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ABSTRACT
The purpose of this study was to develop and validate a theoretical model that
explains the psychosocial effects of beryllium sensitization (BeS) and chronic beryllium
disease (CBD). Sequential, mixed research methods were used. The study population
was current and former workers from Department of Energy laboratories and
manufacturing facilities who have either BeS or CBD. A theoretical model based on
uncertainty in illness and psychosocial adjustment to illness theories was developed. It
was hypothesized that uncertainty had a negative effect on health quality of life unless
mediated by the ability to make psychosocial adjustments to illness. Qualitative study
results supported the proposed model; results from interviews with current and former
workers with BeS or CBD indicated that they experienced psychosocial effects
consistent with uncertainty in illness and psychosocial adjustment to illness theories.
Quantitative study results confirmed the strength and direction of the relationships
between the variables adding further validation to the model. Statistical analyses
confirmed that uncertainty is an independent variable, health quality of life is a
dependent variable, and psychosocial adjustment is an intermediate variable. As
uncertainty increases, health quality of life decreases unless the effects are mediated by
the ability to make psychosocial adjustments to the illness. A multiple regression model
indicated that the domains of psychological distress, social environment and domestic
environment were the best predictors of the mental component summary score for the
study participants. The results also suggested that BeS may have as much, and
possibly more, impact on one’s mental health than CBD. It was concluded that the
theoretical model explaining the psychosocial effects of BeS and CBD has validity. This
v

adds an important new component to the spectrum of CBD – a component that has
implications for treatment as well as workers compensation. Healthcare providers and
support groups should develop programs focused on helping patients develop coping
skills to manage the psychological and social stress of BeS and CBD.
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INTRODUCTION
Over the past 35 years, a substantial amount of research has been published in
the medical literature about chronic beryllium disease (CBD), a rare and incurable
occupational lung disease. As a result, we now have a much better understanding of
the spectrum of this disease. However, a review of the literature reveals a knowledge
gap in one aspect of CBD that is only occasionally discussed among healthcare
providers but is a prominent topic among people with the disease: the psychological
and sociological effects of CBD. This is a report of a research project that was
designed to shed light on this largely unstudied issue.
The purpose of this study was to develop and validate a theoretical model that
explains the psychosocial effects of beryllium sensitization (BeS) and CBD. To
accomplish that, a sequential, mixed-methods research study design was used. There
were three phases to the research project. The first phase was to create a theoretical
model. A plausible model was developed by obtaining anecdotal information from
healthcare providers, researchers, occupational health specialists, and people with the
disease and comparing that information with selected theories described in the medical
and psychology literature. A diagram was developed suggesting the relationships
between controlling, independent, dependent and mediating variables. The model was
socialized among healthcare providers and people with CBD and their feedback
incorporated.
The second phase was to conduct a qualitative study to determine if the
theoretical model could be corroborated by empirical data from in-depth interviews with
a sample of volunteers with either BeS or CBD. Semi-structured interviews were
1

conducted with thirteen current and former workers in various stages of the disease.
The interviews were focused on learning how BeS or CBD had affected their
relationships with family, friends, and co-workers and how it had impacted their mental
health. The data was analyzed to determine if the emergent patterns and themes were
consistent with the constructs of the model.
The third phase was to conduct a quantitative study to measure the psychosocial
effects of BeS and CBD in a larger sample of current and former workers from DOE
laboratories and manufacturing facilities with BeS or CBD. Three valid and reliable
instruments that had been widely used in studying disease in other populations were
used. The survey was mailed to potential participants. One hundred twenty six
respondents completed the questionnaires and returned them to the researcher. The
self-reported questionnaire data were scored and analyzed. The results were
compared to the theoretical model to determine if they were consistent with the
hypothesized relationships between the variables in the model and to identify those
variables that best predicted psychosocial effects.
The results of the study were written into three manuscripts to be submitted for
publication; one paper describing each phase of the study. Each manuscript is
complete and complements they others. They focus on determining whether the
proposed model has validity. They are capable of standing alone but are most
informative when read in sequence. Additional manuscripts are in progress to discuss
related topics discovered during the project (e.g., the psychosocial impact of DOE
policies on workers with BeS or CBD).

2

The study design, model development, qualitative and quantitative research were
all performed by the lead author with guidance from his major professor and committee.
The manuscripts were written entirely by the researcher with review comments provided
by the co-authors.

3

CONCLUSION
Based on the results of this study, it was concluded that the proposed model of
the psychosocial effects of BeS and CBD has validity. The qualitative and quantitative
data affirm the premises and logic of the model; uncertainty is an independent variable,
health quality of life is the dependent variable, and psychosocial adjustment is an
intermediate variable. As uncertainty increases, health quality of life decreases unless
uncertainty is mediated by the ability to make psychosocial adjustments to the illness. It
is concluded that BeS and CBD have a significant psychosocial component that can
have a negative effect on the health quality of life of affected individuals.
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PART 1 – A CONCEPTUAL MODEL OF THE PSYCHOSOCIAL EFFECTS OF
BERYLLIUM SENSITIZATION AND CHRONIC BERYLLIUM DISEASE
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Abstract
Objectives
The objective of this research was to develop a theoretical model that describes
the psychosocial effects of beryllium sensitization (BeS) and chronic beryllium disease
(CBD).
Materials and Methods
The medical, nursing, health education, and psychological literature was
reviewed to identify theories that might support the development of a psychosocial
model of BeS and CBD. A proposed model was synthesized based upon elements
from multiple academic disciplines.
Results
The conceptual model was based on three prominent psychological theories: 1)
health, stress, and coping, 2) uncertainty and illness, and 3) psychosocial adjustment to
illness. The model hypothesizes that workers who are diagnosed with BeS or CBD
experience a great deal of uncertainty that has a detrimental effect on their health
quality of life. The focal relationship in this model is between the independent variable
uncertainty and the dependent variable health quality of life. It is further hypothesized
that the relationship between these two variables is effected by an intermediate
variable; the ability to make psychosocial adjustments to disease.
Conclusions
Creating this model is a step toward filling a void in our understanding of the
natural history of CBD. Once validated it will establish a foundation for future research,

interventions and program evaluations and may lead to changes in the psychological,
social, financial, and disease management support provided to this population.
Key Words
Beryllium; berylliosis, uncertainty in illness; psychosocial adjustment; stress and
coping
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Introduction
A research gap exists in the development and testing of theoretical models which
might explain the psychosocial aspects of beryllium sensitization (BeS) and chronic
beryllium disease (CBD). Such research would help clinicians understand the total
experience of their patients and might suggest changes in the types of psychological,
social, financial, and disease management support provided to workers with BeS or
CBD. The purpose of this research was to develop such a model.
Beryllium is a strong, lightweight metal that is toxic when inhaled into the lungs.
People who work in factories where beryllium is processed are sometimes exposed to
beryllium particles and may develop an allergic reaction to the metal. In some, this
reaction, called BeS, leads to a severe, incurable occupational lung disease known as
CBD.
Beryllium is widely used in the aerospace, electronics, biomedical, defense,
telecommunications and other industries [Jaskula 2010, National Research Council
2007, Rossman, et al. 1991, Kolanz 2001]. The 2010 estimated consumption of
beryllium in the U.S. was 320 metric tons and was valued at about $160 million [Jaskula
2011]. Beryllium consumption is currently dominated by electronics applications [Kelly
and Matos 2011]. The estimate for the number of U.S. workers ever exposed to
beryllium ranges from 800,000 to 1,000,000 [Cullen, et al. 1986, Infante and Newman
2004, Samuel and Maier 2008].
9

Most people who are exposed to beryllium will not experience health effects
because there is a strong genetic susceptibility component to sensitization and
subsequent disease. However, some develop BeS and some of them go on to develop
CBD. Epidemiologic studies have shown that on average, 1-6 percent of exposed
workers develop BeS, although the rates can be as high as 19 percent among workers
with the highest exposures, such as beryllium machinists [Kreiss, et al. 1993, Kreiss, et
al. 1989, Kreiss, et al. 1997, Kreiss, et al. 1996, Maier 2002]. Most workers who are
going to develop BeS tend to do so early on, but follow-up testing over the years
continues to identify workers with BeS—up to 30 percent in one group of workers
[Schuler, et al. 2008].
The percentage of people with BeS who go on to develop CBD is highly variable,
ranging from 10-100 percent in different worker populations [Kreiss, et al. 2007].
Individuals exposed to the highest levels of airborne beryllium dust are at greatest risk
of sensitization, although skin exposure may also be important [Day, et al. 2006].
Recent research suggests that each year, 6-8 percent of people with BeS will develop
CBD [Newman, et al. 2005a]. The latency for converting from BeS to CBD is highly
variable, ranging from 1-12 years in one longitudinal study [Newman, et al. 2005b].
Factors such as particle size, type of beryllium used, amount and duration of exposure
to beryllium, occupation, industry, and genetics all play a role in determining why some
people develop CBD and others do not [Maier 2002, Kreiss, et al. 2007]. Once a
person is exposed to beryllium, they carry a lifelong risk of developing beryllium
10

sensitization or CBD, even if the exposure amount was small or their exposure ceases.
[Kreiss, et al. 2007].
The National Research Council (NRC) [National Research Council 2007]
recognized that the diagnosis of BeS or CBD may be associated with psychosocial
stress and/or loss of income and that there was an absence of published data on those
phenomena. The NRC further suggested that implementation of a comprehensive
beryllium-exposure and disease management program that includes appropriate worker
education and counseling, medical-removal, and protection against lost wages can
minimize such potential adverse consequences [National Research Council 2008].

Materials and Methods
The medical, nursing, health education, and psychological literature was
reviewed to identify theories that might support the development of a psychosocial
model of BeS and CBD. Online searches were conducted to identify publications in the
scientific literature and library searches were conducted to identify and obtain other
scholarly works. Government publications were obtained from agency websites or
through personal requests to contacts in the agencies.
The search was conducted in a sequential manner starting with the medical and
epidemiologic literature related to chronic beryllium disease. This was followed by an
analysis of the nursing literature related to the psychosocial effects of illness. The
psychological literature related to health, stress, and coping was then evaluated.
11

Models from the health education literature were then reviewed to determine how they
might be applied to this project.
The literature was synthesized and a figure of the model was developed. Draft
versions of the model were shared with subject matter experts from various academic
and medical disciplines. Through repeated discussions with experts from multiple
disciplines, the proposed model was further refined. The model was shared with key
informants who had either BeS or CBD to get their feedback. A research plan was
developed to identify how future qualitative and quantitative research projects might be
used to validate the proposed model.

Results
The Natural History of CBD
Beryllium induced lung disease can usually be categorized as either an acute or
chronic disease process [Middleton 1998]. Acute beryllium disease is of historical
significance and was identified in the U.S. in the 1940s [Van Orsdstrand, et al. 1945,
Hardy and Tabershaw 1946] and is considered an irritative chemical phenomenon
related to high exposure levels [Cummings, et al. 2009]. With advances in industrial
hygiene, acute beryllium disease has been virtually eliminated in the U.S. [Middleton
1998]. Despite these historical improvements in workplace exposure conditions, cases
of CBD continue to occur [Newman, et al. 1996].
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According to Newman, Lloyd, and Daniloff [1996] CBD is a systemic disorder that
occurs when a sensitized (i.e., allergic) person’s lungs react with beryllium that has
been inhaled, producing inflammation in the lungs which leads to the formation of lung
granulomas and scarring. They described CBD as a beryllium-specific, cell-mediated
immune response gone awry. Based on their review of historical studies Newman,
Lloyd & Daniloff [1996] concluded that: 1) the disease varies in its clinical presentation,
2) the disease varies in its rate of progression, 3) while removal from exposure may be
medically prudent, it is not known to what extent such restrictions will change the natural
history for more than a minority of patients, and 4) earlier studies did not systematically
review the risk factors for disease progression [Newman, et al. 1996].
The symptoms that cause the patient to seek medical evaluation can include
arthralgia, chest pain, cough, or most commonly dyspnea with relatively mild exertion
[Middleton 1998]. While some persons with CBD die within a few years of diagnosis in
respiratory failure and cor pulmonale, others experience a more insidious downhill
course extending over decades [Newman, et al. 1996]. Workers exposed to persistent
(i.e., non-soluble) beryllium antigen are at lifelong risk of CBD [Kreiss, et al. 2007,
Eisenbud and Lisson 1983].
The diagnosis of CBD is usually preceded by identification of BeS and those
workers that become sensitized are at high risk for developing CBD [Kreiss, et al. 2007].
Conversion from BeS to CBD is highly variable, ranging from 1-12 years in one
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longitudinal study [Newman, et al. 2005a]. The current diagnostic criteria for CBD
include all of the following [Müller-Quernheim, et al. 2006, Maier, et al. 1999]:
1. History of or evidence of beryllium exposure
2. Evidence of an immune response to beryllium, that is, positive response in
blood or bronchoalveolar lavage lymphocytes exposed to differing levels of
beryllium in in vitro cultures (i.e., the beryllium lymphocyte proliferation test or
BeLPT) in two independent tests
3. Symptomatic disease with histological demonstration of noncaseating
granulomas on lung biopsy
Current medical management of CBD involves cessation of beryllium exposure
and use of immunosuppressive drugs [Sood 2009, Sood, et al. 2004] but there is limited
literature regarding the effect of these interventions on the natural history of CBD.
Published mortality rates range from 5.8 to 38% [Newman 1996].
Beryllium Sensitization
The development of the BeLPT [Kreiss, et al. 1989] created a fundamental
change in our knowledge of CBD. According to Maier [2001], it revolutionized our
approach to the diagnosis, screening, and surveillance of beryllium health effects. BeS
is not a disease in its own right and has no symptoms, but it is important because it
identifies a subgroup of exposed workers who are at risk for developing CBD [Council
2007]. A positive BeLPT result differentiates CBD from other lung diseases such as
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sarcoidosis, chronic obstructive pulmonary disease, and hypersensitivity pneumonitis
[Council 2007, Müller-Quernheim, et al. 2006, Newman 1995].
BeLPT results are not always consistent or stable, creating clinical uncertainty
[Deubner, et al. 2001, Stange, et al. 2004, Mroz, et al. 1991, Middleton, et al. 2011,
Middleton, et al. 2006]. Because the test is difficult to perform and results are not
always consistent, most physicians and researchers like to require two independent
abnormal tests in order to categorize a worker as BeS. Greene and Smith [2008]
argued that the empirical uncertainty arising from the probabilistic nature of BeLPT
screening can be highly unsettling for workers who might expect clear guidance from
medical testing. Despite its limitations in test consistency and repeatability, the BeLPT
has been an invaluable tool in the identification of workplace risks in population studies
and intervention effectiveness [Kreiss, et al. 2007] and has led to the identification of
clinically milder cases [National Research Council 2007].
Lung Cancer
In addition to CBD, workers exposed to beryllium also have significantly elevated
risks of lung cancer [Ward, et al. 1992, Steenland and Ward 1991, Sanderson, et al.
2001, Schubauer-Berigan, et al. 2010]. The National Toxicology Program [2009] listed
beryllium as a known carcinogen, as did the International Agency for Research on
Cancer [1993]. However, beryllium exposure is more commonly associated with CBD
than lung cancer and according to the National Institute for Occupational Safety and
Health [2011] controlling beryllium exposure to prevent CBD should also reduce the risk
15

for lung cancer. The reader is referred to the Agency for Toxic Substances and Disease
Registry, Toxicological Profile of Beryllium [2002] and Groth [1980] for comprehensive
reviews of the carcinogenic properties of beryllium.
The Epidemiology of CBD
For the most comprehensive description of the epidemiology of CBD, the reader
is referred to the literature review completed by the National Research Council,
Committee on Toxicology [2007]. This work, along with its companion report [National
ResearchCouncil 2008], were completed for the U.S. Air Force and represent the most
current and complete compilation of the beryllium literature.
The population at risk for CBD is workers in industries where beryllium is
processed in a manner that creates multiple pathways for inhalation and skin contact
with beryllium particles [Day, et al. 2006]. The range of estimates for the number of
U.S. workers exposed to beryllium is 20,000 to 1,000,000 [Cullen, et al. 1986, Infante
and Newman 2004, Samuel and Maier 2008]. Henneberger and others [2004] relied on
sampling data from the Occupational Safety and Health Administration (OSHA) to
estimate that 134,000 U.S. workers were potentially exposed to beryllium. Kreiss, Day,
and Schuler [2007] believed that the number is far higher because OSHA had not
sampled for beryllium in military and nuclear weapons complex workplaces. Other
workplaces, such as those recycling electronics equipment, may also be a source of
previously unsuspected exposure [National Research Council 2007].
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The prevalence of BeS and CBD in exposed workers ranges from 1 - 19% and
from 0.1 - 7.8%, respectively [Maier 2002, Kreiss, et al. 2007]. Table 1.1 provides
prevalence data of BeS and CBD from recent cross-sectional and longitudinal studies
conducted in U.S. industry.

Table 1.1. Prevalence of beryllium sensitization and chronic beryllium disease from
selected epidemiologic studies
Industry

n

BeS %

CBD %

895

2.0%

1.7%

5,173

4.5%

1.6%

Beryllium Production Workers [Kreiss, et
al. 1997]

627

9.4%

4.6%

Beryllium Machinists [Newman, et al.
2001]

235

9.4%

5.5%

Beryllium Ceramics Production
[Henneberger, et al. 2001]

151

9.9%

5.3%

Nuclear Workers [Kreiss, et al. 1993]
Nuclear Workers [Stange, et al. 2001]

BeS=beryllium sensitization; CBD=chronic beryllium disease; %=percent; n=sample
size
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CBD is typically considered only when occupational exposure to beryllium is a
certainty; however, CBD has occurred in occupational and environmental settings
where exposure was unexpected [Middleton 1998]. Individuals who live near plants that
process beryllium may be at greater risk than the general population [Maier, et al. 2008,
Eisenbud, et al. 1949]. The general population is exposed to beryllium through
inhalation of air and consumption of food and drinking water but people who work in
beryllium manufacturing, fabricating, and reclaiming industries are exposed to much
higher levels of beryllium than the general population [Agency for Toxic Substances and
Disease Registry 2002].
The nuclear weapons industry has received substantial attention because of
worker exposure to beryllium. In fact, beryllium disease was recognized among workers
involved in the early development of atomic energy in the World War II era [Van
Orsdstrand, et al. 1945, Hardy 1955]. As nuclear weapons proliferated during the Cold
War, the number of workers in the U.S. Department of Energy (DOE) nuclear complex
grew and the number of workers exposed to beryllium grew proportionately. Beginning
in the late 1980s, clusters of CBD were recognized in workers from nuclear weapons
plants across the U.S. [Kreiss, et al. 1989]. A number of additional epidemiologic
studies of nuclear workers have been completed over the past two decades helping us
to understand the risk of CBD in this population [Kreiss, et al. 1993, Stange, et al. 2001,
Stange, et al. 1996a, Stange, et al. 1996b, Sackett, et al. 2004, Welch, et al. 2004,
Rodrigues, et al. 2008, Arjomandi, et al. 2010, Mikulski, et al. 2011]. These studies and
18

others were chronicled in the DOE regulation (i.e., the Chronic Beryllium Disease
Prevention Program) that was established to prevent the continued occurrence of CBD
[Department of Energy 1999].
Among other things, this rule created the DOE Beryllium-Associated Worker
Registry for current workers who are exposed to beryllium in their current job, or may
have been exposed to beryllium in the past from work conducted at a DOE site
[Department of Energy 2011a]. The goal of the registry is to determine the incidence
and prevalence of BeS and CBD. The data are analyzed to better understand CBD and
to identify those at risk. Another goal is to monitor and evaluate the effectiveness of the
Chronic Beryllium Disease Prevention Program. Coupled with the DOE Former Worker
Medical Screening Program [Department of Energy 2011b], these surveillance
programs provide a mechanism for collecting data about those at risk for BeS and CBD.
The Psychosocial Aspects of CBD
The National Research Council (NRC) recognized that the diagnosis of CBD or
BeS may be associated with psychosocial stress and/or loss of income and that there
was an absence of published data on those phenomena [National Research Council
2007, National Research Council 2008]. The NRC further suggested [2008] that
implementation of a comprehensive beryllium-exposure and disease management
program that includes appropriate worker education and counseling, medical-removal,
and protection against lost wages can minimize such potential adverse consequences.
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At the 3rd Annual International Conference on Beryllium Disease, Newman [2007]
made a presentation identifying unanswered questions related to CBD. He argued that
there was still much to be learned about the neuro-psychological and social effects of
CBD on BeS and CBD patients. He reported that his patients asked how beryllium will
affect their employment, finances, insurability, workers compensation, personal wellbeing, and social lives. Later at the same conference, Cragle [2007] encouraged
researchers to consider the sensitized/CBD patient as a whole human being and asked,
“Where are the social scientists?”
In 1999, at the Conference on Beryllium Effects on Worker Health, Henneberger
suggested that it was important to survey former employees to estimate the full extent of
the problem and to understand the natural history of CBD [Henneberger and Kreiss
1999]. In 2008, at the Third International Conference on Beryllium Particulates and
Their Detection, McCawley [2008] presented the results of a survey of members of the
Beryllium Health and Safety Committee to identify the most important topics for future
research. In the area of health effects, McCawley reported the second highest priority
was to “identify opportunities for therapeutic interventions (pre-CBD) or specific
therapies for CBD” and suggested that a research plan needed to be developed to help
people with BeS and CBD.
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Current Theoretical Perspectives and Relevant Studies
Stress and Coping Theory
Stress is a term that originated in the disciplines of physics and engineering.
Early research on human stress was conducted by scientists in the fields of biology,
physiology, and psychology. It was Cannon [1929] who coined the enduring term “fight
or flight” to describe the human response to stress. Endocrinologist Hans Selye [1936]
was the father of modern stress research and was the first to publish a paper on the
biological syndrome of stress. Over the next twenty years he further explored the
concept as it related to disease in man, eventually publishing Stress and Life [Selye
1956]. In this seminal work, he defined three stages of stress: alarm reaction, stage of
resistance, and stage of exhaustion. He described the alarm stage as a generalized
call to arms of the defensive forces in the organism. Following this was a stage of
biological adaptation of the organs to the stress. After prolonged exposure, the
adaptation was eventually lost and the animal entered the stage of exhaustion. At the
end of a life under stress, there was a premature aging due to wear and tear. To
describe this progression, he used the term general adaptation syndrome [Selye 1956].
Thus began the study of stress and illness.
While Selye initially focused on biological stress, others turned their attention to
the concept of psychological stress. Lazarus [1966] considered the field of stress a
collective term that included physiological, sociological, and psychological phenomena
and their respective concepts. He argued that these diverse terms could be combined
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in the same study. Lazarus extended the general adaptation syndrome [1966] by
incorporating the concepts of stress appraisal and coping. He suggested that for a
psychosocial situation to be stressful, it must be appraised as such. That is, one must
determine whether a situation is potentially threatening, constitutes a harm/loss, is
challenging, or is benign. He theorized that this assessment occurred during primary
and secondary appraisals. The primary appraisal includes the perception of how
stressful the stimulus is and the secondary appraisal estimates whether one has
adequate resources to deal with the problem. He defined coping as the strategies one
employs for dealing with stress and that when the individual discovers some important
motive or value is being threatened, coping activity is mobilized by this threat, by virtue
of the cognition that “my life, health, wealth, or cherished social relationships are in
danger.” Lazarus [1966] referred to these coping modes as direct action, vigilance, and
avoidance.
Selye later published a new model [1975] that divided stress into eustress and
distress. This differentiated stress that enhanced physical or mental functioning (i.e.,
eustress) and persistent stress that was not resolved through coping and adaptation
(i.e., distress). Eustress is positive adaptation to stress and is typified by activities such
as exercise to build strength and cardiovascular capacity. Distress results in negative
functioning and may lead to anxiety, depression and/or physical ailment. This model
more accurately represented both the positive and negative potential associated with
stress.
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Holroyd and Lazarus [1982] explored the linkage between stress, coping, and
illness, describing three ways that stress might lead to somatic illness. The first was by
the disruption of tissue function from neural and hormonal outpourings (e.g., pounding
heart, sweating, trembling, etc.). The second was by engaging in coping activities that
were damaging to health (e.g., tobacco use, alcohol consumption, poor diet). The third
way that stress might lead to disease is by psychological and/or sociological factors
which lead the person to minimize the significance of symptoms or to fail to comply with
treatment programs (e.g., avoidance of doctors). They concluded that whether stress
led to somatic illness via one of these mechanisms was influenced by a person’s coping
methods and skills.
Lazarus and Folkman [1991] recognized that people exhibited different coping
styles when confronted with stress. They suggested that coping styles are broad,
pervasive, encompassing ways of relating to particular types of situations such as
ambiguous or clear, imminent or distant, temporary or chronic, evaluative or
nonevaluative. They also recognized that coping styles are dynamic and subject to the
personality of the individual. These dynamic properties make for a diversity of strategies
for those coping with illness. Stress can also have a distinct physiologic effect.
O’Leary [1990] reviewed the empirical evidence linking emotional stress to
immune function in humans. She reported that chronic stress has been associated with
suppression of immune function, and that there is evidence that the immune system
may not adapt over time [O'Leary 1990]. There is evidence that psychosocial stress
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influences a variety of immune functions and on several disease processes. This
presents some provocative questions about the interaction between psychosocial and
physiological stress associated with immune mediated diseases, like CBD.
As the theory of stress and coping evolved and matured, key concepts became
more defined. Folkman [2011] recognized that the scope of coping had been
broadened to include regulation of positive well-being in the face of stress. In addition,
research is now being conducted on future-oriented coping, interpersonal coping, and
religious and spiritual coping. Models have been developed to explain the concept of
stress and coping in society. One such model that explains how stress and coping
theory applies to health and well-being is the Transactional Model of Stress and Coping.
Transactional Model of Stress and Coping
Understanding stress and coping is essential to health education, health
promotion, and disease prevention [Glanz, et al. 2008] and the Transactional Model of
Stress and Coping is a framework for evaluating processes of coping with stressful
events. Glanz and Schwartz articulated the constructs of the model which is rooted in
the cognitive theory of psychological stress and coping developed by Lazarus and
Folkman [1984]. The theory is transactional in that the person and the environment are
viewed as being in a dynamic, mutually reciprocal, bi-directional relationship. Stress is
conceptualized as a relationship between the person and the environment that is
appraised by the person as taxing or exceeding his or her resources and as
endangering well-being [Glanz, et al. 2008]. The theory identifies two processes 24

cognitive appraisal (primary and secondary) and coping strategies (problem, emotion,
and meaning-based) as critical mediators of stressful person-environment relationships
and their immediate and long-term outcomes including emotional well-being, functional
status, and health behaviors [Glanz, et al. 2008]. Because stress effects people
differently, the ability to cope with stress influences decisions about seeking medical
care and social support and whether one believes the advice of professionals. This
model serves as the theoretical basis for many health education and disease prevention
programs.
Psychosocial Adjustment to Illness Theory
The ability of humans to adjust to threatening events is a derivative of stress and
coping theory. Taylor [1983] observed that one of the most impressive qualities of the
human psyche is its ability to successfully withstand severe personal tragedy. Based on
her experience with cancer patients, cardiac patients, rape victims, and other individuals
facing life-threatening events [Taylor 1983], she argued that when an individual has
experienced a life-threatening event, the readjustment process focused around three
themes: 1) a search for meaning in the experience, 2) an attempt to regain mastery
over the event in particular and over one’s life more generally, and 3) an effort to
enhance one’s self-esteem, to feel good about oneself again despite the personal
setback.
How one adjusts to illness has been the subject of much research over the past
thirty years [Kalman, et al. 1983, Zyzanski, et al. 1981]. Mechanic [1978] noted that
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what interested behavioral scientists was the tremendous variability in response to what
was presumably the same illness condition. While one person hardly acknowledged a
condition and refused to allow it to alter his/her life, another with a milder form of the
same condition would display profound social and psychological disabilities.
Psychosocial adaptation to chronic illness and disability has been the subject of
more research as the prevalence of chronic disease increases in our society. Livneh
and Antonak [1997] suggested that the prolonged course of treatment, the uncertain
prognosis, the constant and intense psychological stress, the gradually increasing
interference with the performance of daily activities and life roles, and the associated
impact on family and friends all combine to create a profound effect on the lives of
persons with chronic illness and disabilities. Cassileth and others [1984] compared the
psychosocial status of five groups of patients with chronic illness (i.e., arthritis, diabetes,
cancer, renal disease, and dermatologic disorders) and found them remarkably adaptive
in comparison to patients with depression. They concluded that psychological status
was independent of the specific diagnosis for these chronic diseases.
Derogatis was one of the early pioneers in this field and he, along with Abeloff
and Melisaratos [1979], reported on the psychological coping mechanisms in patients
with metastatic breast cancer. They found that, in general, the long-term survivors had
higher psychological distress levels than the short-term survivors. They also
established that cancer patients whose coping styles facilitated external, conscious
expression of negative emotions and psychological distress appeared to survive longer
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while patients whose coping styles involved suppression or denial of affect or
psychological distress had a shorter length of survival. They [Derogatis, et al. 1979]
suggested that psychological interventions could be redesigned to put patients more in
touch with their emotions and possibly promote a more successful psychological
outcome. This early research led Derogatis to explore the development of psychometric
scales that could be used to measure the ability to adjust to illness.
The Global Adjustment to Illness Scale (GAIS) was developed as an instrument
to measure the prevalence of psychiatric disorders among cancer patients [Derogatis, et
al. 1983]. In this study the GAIS, along with two other instruments, were administered to
a sample of 215 cancer patients. The results of the survey indicated that 47% had a
psychiatric diagnosis and that approximately 68% of those diagnoses consisted of
adjustment disorders. The authors further suggested that pervasive emotional distress
and dysphoria often associated with cancer may not be an inherent part of the
neoplastic disease, but rather a separate and potentially treatable condition. This study
provided an epidemiologic benchmark for the prevalence of psychiatric disorders among
cancer patients and has had far-reaching implications for treatment and therapy. It also
motivated Derogatis to further refine his psychometric instrument.
In 1986, Derogatis introduced the interview-based Psychosocial Adjustment to
Illness Scale (PAIS®) and a self-reporting version (PAIS-SR®) to assess the
psychological and social adjustment of medical patients, or members of their immediate
families, to the patient’s illness. The PAIS® and PAIS-SR® were developed to reflect
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seven principal domains [Derogatis 1986], all of which had been shown to have a high
relevancy for adjustment to medical illness. The seven domains include:
1. health care orientation
2. vocational empowerment
3. domestic environment
4. sexual relationships
5. extended family relationships
6. social environment
7. psychological distress
The instruments were tested for factor structure, reliability, and validity and a
library of six normative groups was developed (lung cancer patients, renal dialysis
patients, acute burn patients, hypertensive patients, cardiac bypass patients, and
heterogeneous cancer patients). Later, other researchers [Merluzzi and MartinezSanchez 1997, Rodrigue, et al. 2000] conducted additional factor structure analyses on
the PAIS-SR®.
While Derogatis [1986] noted that there were more than two dozen instruments
available to assess psychiatric patients, he developed this instrument because there
was a dearth of tools for measuring the psychosocial status of non-psychiatric patients.
Others [Cain, et al. 1986, Jenkins, et al. 1991, Northouse, et al. 2000, Greer, et al.
1992] began using the instrument to describe the psychosocial illness experience for
patients with cancer and occasionally for other conditions like kidney disease [Soskolne
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and De-Nour 1989, De-Nour 1982] chronic lung disease [Stubbing, et al. 1998], burns
[Browne, et al. 1985], and multiple sclerosis [Pakenham 1999]. The PAIS® and PAISSR® were tools that helped fill the void in this field of research.
Folkman and Greer [2000] provided an appraisal and coping framework that has
helped tie adjustment to illness theory to the empirical data generated by research tools
like the PAIS®. They suggested a model therapeutic program aimed at improving the
psychological well-being of patients facing serious illness. Since the 1990s,
psychosocial interventions have become increasingly more relevant as evidenced by
the meta analysis that Rehse and Pukrop [2003] conducted on 37 controlled outcome
studies. It is now widely recognized [Sharpe and Curran 2006] that understanding the
process by which most individuals adjust to illness offers important insights to enhance
the efficacy of interventions that facilitate psychological adjustment. Helping individuals
adjust to their illness has become a priority, especially for those with chronic diseases.
Uncertainty and Illness Theory
The uncertainty and illness theory is another attempt to explain the human illness
experience. Spawned from stress and coping theory, uncertainty and illness has been
of particular interest to clinicians and researchers trying to understand the challenges of
patients coping with chronic illness.
According to Brashers [2001] uncertainty exists when details of situations are
ambiguous, complex, unpredictable, or probabilistic; when information is unavailable or
inconsistent; and when people feel insecure in their own state of knowledge or the state
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of knowledge in general. Babrow, Hines, and Kasch [2000] further postulated that
because uncertainty is multilayered, interconnected, and temporal, people experience
multiple sources of uncertainty at once, that manipulating one type of uncertainty can
impact (e.g., increase or decrease) uncertainties of other types, and that experiences of
uncertainty are ongoing and changing features of life.
After an exhaustive search of the psychological literature, Norton [1975]
concluded that no matter the source, when an event is judged to be uncertain, it will
contain one or more of the following eight dimensions: 1) multiple meanings; 2)
vagueness; 3) probability; 4) unstructured; 5) lack of information; 6) ambiguity; 7)
inconsistencies and contradictions; and 8) unclear. This provided a framework for the
concept of uncertainty that has been used in research across multiple disciplines.
Babrow, Kasch, and Ford [1998] identified uncertainty as a central part of the
experience of illness. They described multiple sources of variation within the concept of
uncertainty including, complexity, qualities of information, probability, structure of
information and lay epistemology. For example, clarity (e.g., the use of medical jargon),
accuracy (e.g., laboratory analytical methods), and ambiguity (e.g., different
interpretations of results) are all qualities of information that can vary greatly. They
attempted to reconcile sources of variation in conceptions of uncertainty and synthesize
more specific conceptions of uncertainty in illness. Recognizing what contributes to
uncertainty in illness and how it can be managed remains a daunting assignment. One
of the pioneers in this effort was Dr. Merle Mishel.
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Mishel [1981] investigated the role of uncertainty as a significant variable
influencing patients’ experiences in illness, treatment, and hospitalization. She proposed
a model of perceived uncertainty in illness and developed an instrument (i.e., the Mishel
Uncertainty in Illness Scale – MUIS) for measuring uncertainty in symptomatology,
diagnosis, treatment, relationship with caregivers, and planning for the future. She
continued to refine the structure of the model [Mishel 1983, Mishel 1984, Mishel and
Braden 1988] and the MUIS was applied to a variety of populations [Mishel, et al. 1984,
Mishel and Murdaugh 1987]. In 1988 she published a seminal paper [Mishel 1988] on
uncertainty in illness. In this paper she defined uncertainty as the inability to determine
the meaning of illness-related events and stated the fundamental belief that uncertainty
concerning what will happen, what the consequences of an event are, and what the
event means, are important to a person with any illness. Furthermore, she argued that
managing the uncertainty associated with an illness and its treatment may be an
essential task in adaptation. She encouraged further research applying the model and
MUIS in different patient populations and varied settings.
While the model had been previously applied to acute illnesses or those in a
downward illness trajectory, little had been done to understand uncertainty in chronic
diseases. Mishel [1988] reconceptualized the uncertainty in illness theory to address
the experience of living with continual, constant uncertainty in either a chronic illness or
in an illness with a treatable acute phase and possible eventual recurrence. This was
based in part on the qualitative observation that the longer chronically ill subjects lived
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with continual uncertainty, the more positively they evaluated the uncertainty. This
supported the argument that uncertainty can be a positive experience but was contrary
to the cultural value that uncertainty is an aversive experience and, except in an
extreme situation, is definitely not preferable to certainty.
Drawing on chaos theory, Michel [1990] postulated that uncertainty surrounding a
chronic illness or life-threatening condition qualified as a sufficient fluctuation to threaten
the preexisting organization of the person. Michel viewed uncertainty in illness as:
“A fluctuation that begins in only one part of the human system and, according to
chaos theory, can either regress and cause no particular disruption or spread to
the whole system. As uncertain disease related factors, like severity of the
illness, success of treatment, impact of illness on one’s life, and ability to pursue
life’s dreams and ambitions, are introduced into the person’s life the uncertainty
competes with the person’s previous mode of functioning. As the concentration
of the uncertainty expands, it can exceed the person’s level of tolerance, causing
the personal system to become unstable. The uncertainty that early in the illness
was the source of fluctuation, later in the illness becomes the foundation on
which the person constructs a new sense of order.” [Michel 1990, p. 259]
Thus, she postulated [Mishel 1990] that uncertainty is used by individuals to
reformulate their view of life and that this new view of life allows one to view uncertainty
as an opportunity rather than a danger or threat. Mishel [1990] encouraged health care
providers to adopt a probabilistic rather than a mechanistic paradigm. That is, accept
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uncertainty as a natural, inherent part of reality that is not determinable with precision
and abandon the view that uncertainty is the enemy and must be eliminated.
Uncertainty and illness theory has matured over thirty years and become a
cornerstone for understanding the psychosocial effects of chronic disease. In studies
examining the adjustment to uncertainty in illness [Mishel 1990], the most common
conclusion is that high uncertainty is related to high emotional distress, anxiety,
depression, and fatigue. This progression has been supported by the work of others
beside Mishel who have conducted research to clarify the concepts within the theory
[Mishel 1981, Christman, et al. 1988, Mishel 1997, Mishel, et al. 1991, Webster, et al.
1988, White and Frasure-Smith 1995, Johnson, et al. 2006, Bailey, et al. 2010,
Sammarco and Konecny 2008], understand how nursing interventions can be used to
manage uncertainty [McCormick 2002], to illuminate processes of coping with
uncertainty [Neville 2003, Cohen 1993], and to conceptualize how adaptation to
uncertainty effects health-related quality of life [Babrow and Kline 2000]. One chronic
disease to which uncertainty and illness theory has been successfully applied is
prostate cancer.
Psychosocial Effects of Prostate Cancer
According to the American Cancer Society [2010], prostate cancer is the second
most commonly diagnosed cancer among men in the U.S. and the second most
common cause of cancer death among men. In 2010, an estimated 217,730 new cases
of prostate cancer were diagnosed in the U.S. [American Cancer Society 2010].
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Changes in the incidence of prostate cancer over the past 20 years reflect the
widespread use of the prostate specific antigen (PSA) screening tool [American Cancer
Society 2010]. According to Tombal [2006], the PSA has led to a dramatic increase in
the number of patients diagnosed with prostate cancer, a significant number of them
being non-clinically significant. The diagnosis of prostate cancer has well-described
psychosocial difficulties [Eton and Lepore 2002] that vary across stages of disease and
types of treatment. Some men, who are asymptomatic and have low-risk, early stage
cancer, are eligible for active surveillance which offers a means to monitor the cancer
while delaying treatment [Eton and Lepore 2002, Warlick, et al. 2006]. This is in contrast
to watchful waiting which is a conservative management strategy for men who are more
likely to die from co-morbidities [Warlick, et al. 2006, Oliffe, et al. 2009]. The result of
this phenomenon is that there are now a large number of men living with localized
prostate cancer and the uncertainty that it bestows.
Germino, Mishel and others [Germino, et al. 1998] began applying uncertainty of
illness theory to prostate cancer soon after the PSA-stimulated diagnosis boom. Since
then, studies [Shaha, et al. 2008] have shown that prostate cancer is a disease fraught
with uncertainty that often makes adjustment to the illness difficult. To gain a richer
understanding of uncertainty in men undergoing watchful waiting or active surveillance,
qualitative and quantitative studies [Oliffe, et al. 2009, Wallace 2003, Bailey, et al. 2007,
Kazer, et al. 2011, Bailey Jr, et al. 2011] were conducted by a number of researchers.
Collectively, this body of knowledge has established a foundation from which
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researchers [Mishel, et al. 2002, Steginga, et al. 2008, Mishel, et al. 2009] can design
and conduct randomized clinical trials to evaluate the efficacy of psychosocial
interventions. Those experiments and a number of others were recently summarized
[Chambers, et al. 2011] in the literature. With evidence on the efficacy of interventions
in hand, researchers [Kershaw, et al. 2008, Song, et al. 2010] are now reporting the
results of longitudinal studies to measure the change in quality of life among prostate
cancer patients and their partners.
Discussion
The example of prostate cancer suggests a possible path forward for the study of
the psychosocial effects of CBD. In this example, researchers recognized that prostate
cancer was unique from other types of cancers and studied both the physical and
psychological aspects of the natural history of the disease. They conducted qualitative
studies to gain an initial understanding of the psychosocial problems confronting
patients and their partners. Then they developed a theory base (i.e., uncertainty of
illness) and conducted quantitative studies to refine a model that accurately described
the psychosocial component of prostate cancer. Following this, theory-based
interventions were developed, implemented, and evaluated. Finally, longitudinal studies
were conducted to determine the long-term effect of the intervention in the study
population. Executing a similar systematic approach should be the goal for researchers
and clinicians studying the psychosocial effects of BeS and CBD.
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There are psychological theories described in the literature that help us
understand stress, coping, and chronic illness. We know that the stress of chronic
diseases, like CBD, affects people differently. Fortunately, humans have a remarkable
ability to adapt to stress when faced with chronic disease. The Transactional Model of
Stress and Coping was developed to help us understand the inter-relatedness of stress
and coping concepts to health and well-being. This model is commonly used by health
professionals who are developing interventions to help people cope with stress. There
are valid and reliable instruments, like the MUIS and PAIS®, which help us measure the
psychosocial effects of stress and chronic disease. These instruments have been used
in a variety of studies of chronic illnesses, like prostate cancer, but never to study
individuals with CBD.
The Model
The conceptual model is based on three prominent psychological theories: 1)
health, stress, and coping, 2) uncertainty and illness, and 3) psychosocial adjustment to
illness. The model supports the hypothesis that workers who are diagnosed with BeS
or CBD experience a great deal of uncertainty and that has a detrimental effect on their
health status. The focal relationship in this model is between the independent variable
uncertainty (i.e., the characteristic being observed) and the dependent variable health
quality of life (i.e., the outcome of interest). It is suspected that the relationship between
these two variables may be partially mediated by an intermediate variable, the ability to
make psychosocial adjustments to disease. Figure 1.1 illustrates the conceptual model.
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Controlling Variables
(Potential Confounders)
•
•
•
•
•
•

Antecedents
•
•
•
•
•

Genetic susceptibility
Exposure
Sensitization
Symptoms of disease
CBD diagnosis
Independent Variables
(Uncertainty)
•
•
•
•
•
•

Focal
Relationship

Ambiguity
Inconsistency
Vagueness
Unpredictability
Lack of information
Unfamiliarity
Intermediate Variables - Mediator
(Psychosocial Adjustment)
•
•
•
•
•
•
•

Exclusionary
Strategy

Age
Education
Socioeconomic status
Vocation
Marital Status
Healthcare experiences

Healthcare orientation
Vocational environment
Domestic environment
Sexual relationships
Extended family relationships
Social Environment
Psychological distress

Dependent Variables
(Health Quality of Life)
•
•
•
•
•
•
•
•

Vitality
Physical functioning
Bodily pain
General health perceptions
Physical role functioning
Emotional role functioning
Social role functioning
Mental health

Inclusionary
Strategy

Figure 1.1. Conceptual model of the psychosocial effects of chronic beryllium disease
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As depicted in Figure 1.1 there are five antecedents (i.e., preceding events) that
influence the independent variable: 1) host (genetic) susceptibility to beryllium disease,
2) exposure to beryllium in the workplace, 3) sensitization (allergy) to beryllium, 4)
symptoms of CBD, and 5) diagnosis of CBD. Exposure to beryllium in the workplace is
the most critical antecedent. Exposure is necessary but not sufficient when acting alone
(i.e., one cannot get CBD if he/she is never exposed to beryllium, but exposure does not
guarantee that disease will occur). Exposure must be combined with host susceptibility,
sensitization, symptoms of disease, and/or diagnosis of CBD to create a necessary and
sufficient combination of factors to activate the model.
There are at least six potential confounding variables to be considered: 1) age, 2)
education level, 3) socioeconomic status, 4) vocation, 5) marital status, and 6) history of
involvement with the healthcare system. These variables may distort the truth because
they may be associated with both uncertainty and health status. For example,
individuals with a higher socioeconomic status may have less uncertainty (e.g., a more
predictable life) because they have a stable income, food and shelter. They also may
have greater access to healthcare or seek and comply with medical recommendations
better, which translates to regular physical exams and screenings that help prevent the
development of chronic diseases (i.e., greater physical functioning).
In the model, uncertainty is proposed as an independent variable that influences
health quality of life. This proposition is based on the research conducted by Mishel
[1981] to determine how uncertainty influences patients’ experiences in illness,
treatment, and hospitalization. She developed a model of perceived uncertainty in
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illness and developed an instrument (i.e., the Mishel Uncertainty in Illness Scale –
MUIS) for measuring uncertainty in symptoms, diagnosis, treatment, relationship with
caregivers, and planning for the future. The MUIS has six primary domains: 1)
ambiguity, 2) inconsistency, 3) vagueness, 4) unpredictability, 5) lack of information,
and 6) unfamiliarity. In studies examining the adjustment to uncertainty in illness [1990],
the most common conclusion was that high uncertainty was related to high emotional
distress, anxiety, depression, and fatigue.
A proposed intermediate variable is psychosocial adjustment to illness. This
proposition is based on the research conducted by Derogatis (1986). He introduced the
Psychosocial Adjustment to Illness Scale (PAIS®) to assess the psychological and
social adjustment of medical patients, or members of their immediate families, to the
patient’s illness. The PAIS® was developed to reflect seven principal domains
[Derogatis 1986], all of which had been shown to have a high relevancy for adjustment
to medical illness: 1) health care orientation, 2) vocational empowerment, 3) domestic
environment, 4) sexual relationships, 5) extended family relationships, 6) social
environment, and 7) psychological distress. An example of the mediating role this
variable may play is illustrated as follows. The lag period between when a person
becomes sensitized and develops symptoms of CBD is difficult to predict and may
range from months to decades. This period may be tempered by the individual’s
healthcare orientation (e.g., their general approach to taking care of their health). That
is, someone who is very attentive to their health needs and exhibits healthy behaviors,
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such as regular exercising and maintaining a proportional weight, may postpone the
onset of CBD symptoms.
In the model, the outcome of interest is health quality of life. This includes both
the physical and mental domains. The Rand Corporation developed an instrument (SF36v2®, Quality Metric Incorporated) that measures eight health concepts: 1) vitality, 2)
physical functioning, 3) bodily pain, 4) general health perceptions, 5) physical role
functioning, 6) emotional role functioning, 7) social role functioning, and 8) mental
health. This is a valid and reliable scale that is widely used to measure health quality of
life among sick and well populations. Based on anecdotal reports, a hypothetical test
case has been constructed to illustrate how this model functions.
Test Case
A skilled machinist applied for a job at a metal machining and fabrication shop
where various aircraft parts were manufactured from beryllium and other metals.
Whether he was genetically susceptible to beryllium was unknown. Prior to his
employment, he was given a pre-employment physical examination and screened for
beryllium sensitization using the BeLPT. The BeLPT was normal, he was declared fit
for duty, and hired.
He worked in the factory for 5 years and was promoted to journeyman machinist.
Each year he had the BeLPT and the result was normal. Industrial hygiene samples
were occasionally collected in the factory and 90% of the results showed that airborne
beryllium concentrations were less than the limit of detection of 0.05 micrograms per
cubic meter of air (μg/m3) and all of the results were less than 0.1 μg/m3. This was 20
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times less than the Occupational Safety and Health Administration (OSHA) standard so
management believed the exposure levels were safe. Several breathing zone samples
were collected from various machinists but none were ever collected directly from the
breathing zone of this Worker.
During the Worker’s annual physical at the start of his sixth year, his BeLPT
result was abnormal. The plant nurse told him false positives were common with this
test and that they needed to repeat the BeLPT to confirm the first result. She drew
blood for a second BeLPT and sent it to the laboratory for analysis. The results,
received six-weeks later, were reported as “borderline.” The plant nurse told the Worker
that a third test was needed because a borderline result was neither positive nor
negative. They repeated the test and waited six more weeks for results. This result
was also abnormal. The Company Doctor told the Worker that he was sensitized to
beryllium. The Worker had no symptoms and his pulmonary function tests were normal.
The Doctor told him he could not say with certainty if or when he might develop CBD.
He said some people never developed symptoms and others developed symptoms
within a few months; everyone was different. In the meantime, it was prudent that he no
longer work with beryllium.
The Worker’s supervisor told him that he would not be able to come back to his
machinist position because it was company policy that a sensitized worker could not
work around beryllium and they did not have any machinist positions where he would
not be potentially exposed to beryllium. He could transfer to the grounds maintenance
crew, however, if he chose to do that he would have to work at a 50% pay reduction.
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The Worker went home and told his wife that he would have to take a 50% pay
reduction and work on the grounds crew if he wanted to stay at the factory. She was
concerned about that but was mostly worried about what would happen if he developed
CBD. The Worker wondered if he was going to have to change careers. He had
always been a machinist and did not know what else he could do and make an
equivalent salary. He wondered if he could make an insurance claim for disability or
workers compensation because he was sensitized to beryllium.
In this example, the reader may have recognized two of the antecedents (i.e.,
exposure and sensitization) along with several sources of uncertainty. Ambiguity was
represented by the alternating normal and abnormal BeLPT results. Vagueness was
represented by the industrial hygiene sampling results that were reported as less than
the limit of detection. Unpredictability was present when the Doctor described the
natural history of CBD. Lack of information was present when the Worker wondered
about whether he was eligible for a workers compensation or disability insurance claim.
Unfamiliarity was present when the Worker wondered about what other trade he could
learn.
The effect of this uncertainty may be mediated (i.e., modified) by the Worker’s
individual situation and life experiences. For example, if his spouse had a job in the
healthcare field that paid well that might mediate some of the healthcare and financial
uncertainty. If he friends from the factory that also had become sensitized to beryllium
and they joined a local CBD support group that might mediate the social functioning. If
his brother owned a construction business and he was able to work for him that might
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mediate the vocational uncertainty. This test case is a composite of actual scenarios
and demonstrates the potential for uncertainty with BeS and CBD.
Validating the Model
Following the path demonstrated by researchers studying the psychosocial
effects of prostate cancer, both qualitative and quantitative research methods should
can be used to determine whether empirical data supports this conceptual model. Both
inclusionary and exclusionary analytical strategies should be employed. The
exclusionary strategy should seek to demonstrate that there is no relationship between
uncertainty, psychosocial adjustment, and health status. The inclusionary strategy
should seek to demonstrate that there is a relationship between these variables.
A qualitative study, involve a group of 12-15 current and former workers with
either BeS or CBD, will be conducted to help determine if the model has validity. The
participants will be interviewed to gain a richer understanding of their disease
experience. Semi-structured interviews will identify what effect their disease has had on
their mental health and their relationships with family, friends and co-workers.
Transcripts of the interviews will be analyzed to determine the degree to which their
experience supports the conceptual model.
A quantitative study will be conducted to provide data that can be triangulated
with the qualitative data to determine the validity of the conceptual model. A cohort of
current and former workers from the U.S. Department of Energy complex who have
been diagnosed with BeS or CBD will be surveyed. Each of these workers/former
workers will be asked to complete four questionnaires (demographics and work history,
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SF-36v2®, MUIS, and PAIS-SR®) designed to describe their work history/
demographics and to measure health quality of life, uncertainty and illness, and
psychosocial adjustment to illness.

Conclusion
Creating this model is a step toward filling a void in our understanding of the
natural history of CBD. Once validated, it will establish a foundation for future research
and program evaluations and may lead to changes in the psychological, social,
financial, and disease management support provided to this population.
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Abstract
Background
The objective of this research was to describe the psychosocial effects of beryllium
sensitization (BeS) and chronic beryllium disease (CBD) for a sample of current and
former workers from Department of Energy facilities in Oak Ridge, TN.
Methods
Semi-structured interviews were conducted with 13 participants. Interviews were
recorded and transcribed. The responses were coded and analyzed to identify patterns
and themes and to learn about their experiences. The results were compared to a
theoretical model developed by the authors.
Results
Participants described ambiguity, inconsistency, vagueness, unpredictability, lack of
information, and unfamiliarity that was consistent with the Michel Uncertainty in Illness
Scale. They also described how they adjusted to their illness in a manner aligned with
the Derogatis’ Psychosocial Adjustment to Illness theory.
Conclusions
Based on the results of this study, it appears appropriate to apply Uncertainty in Illness
and Psychosocial Adjustment to Illness theories to BeS and CBD. Uncertainty may be
considered an independent variable and psychosocial adjustment an intermediate
variable in the study of the psychosocial effects of BeS and CBD.
Key Words
Beryllium; uncertainty in illness; psychosocial adjustment; stress and coping
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Introduction
This is a report of a qualitative study of the psychosocial effects of beryllium
sensitization (BeS) and chronic beryllium disease (CBD). The aim of the study was to
collect and analyze empirical data to help validate a proposed model of the
psychosocial effects of CBD and to aid in the design and evaluation of programs for
workers with BeS or CBD and their families.
Beryllium is a strong, lightweight metal that is toxic when inhaled into the lungs.
People who work in factories where beryllium is processed are sometimes exposed to
beryllium particles and may develop an allergic reaction to the metal. In some, an
immune response (BeS) leads to a severe, incurable occupational lung disease known
as CBD.
Frequently reported symptoms of CBD include one or more of the following:
dyspnea on exertion, cough, fever, night sweats, and chest pain and, less frequently,
arthralgia, fatigue, weight loss, or appetite loss [Maier 2002]. On physical examination, a
doctor may find signs such as rales, cyanosis, digital clubbing, or lymphadenopathy. A
radiograph of the lungs may show many small scars. Patients may also have an
abnormal pulmonary function test and peripheral blood beryllium-induced lymphocyte
proliferation test (BeLPT) [Samuel and Maier 2008]. Examination of lung tissue under
the microscope may show granulomas. CBD may be confused with other lung diseases,
especially sarcoidosis [Müller-Quernheim, et al. 2006, Infante and Newman 2004]. In
advanced cases, there may be manifestations of right-sided heart failure, including cor
pulmonale [Samuel and Maier 2008].
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Most people who are exposed to beryllium will not experience health effects.
However, some develop BeS and some of them go on to develop CBD. Epidemiologic
studies have shown that a range of 1-6 percent of exposed workers develop BeS,
although the rates can be as high as 19 percent among workers with the highest
exposures, such as beryllium machinists [Maier 2002, Kreiss, et al. 1993, Kreiss, et al.
1989, Kreiss, et al. 1997, Kreiss, et al. 1996, Schuler, et al. 2008]. Most workers who
are going to develop BeS tend to do so early on, but follow-up testing over the years
continues to identify workers with BeS—up to 30 percent in one group of workers
[Schuler, et al. 2008].
The percentage of people with BeS who go on to develop CBD is highly variable,
ranging from 10-100 percent in different worker populations [Kreiss, et al. 2007].
Individuals exposed to the highest levels of airborne beryllium dust are at greatest risk,
although skin exposure may play a role in sensitization [Day, et al. 2006]. In each
population, a certain percentage of people with BeS will not have CBD at the time the
BeS is discovered. Recent research suggests that each year, 6-8 percent of nondiseased people with BeS will develop CBD [Newman, et al. 2005a]. The latency for
converting from BeS to CBD is highly variable, ranging from 1-12 years in one
longitudinal study [Newman, et al. 2005b]. Factors such as particle size, type of
beryllium used, amount and duration of exposure to beryllium, occupation, industry, and
genetics all play a role in determining why some BeS people develop CBD and others
do not [Maier 2002, Kreiss, et al. 2007]. Once a person is exposed to beryllium, he/she
carries a lifelong risk of developing beryllium sensitization or CBD, even if the exposure
amount was small or exposure has ended [Kreiss, et al. 2007].
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Beryllium is widely used in the aerospace, electronics, biomedical, defense,
telecommunications and other industries [Jaskula 2011]. Beryllium consumption is
currently dominated by electronics applications [Kelly and Matos 2011]. The 2010
estimated consumption of beryllium in the U.S. was 320 metric tons and was valued at
about $160 million [Jaskula 2011]. The estimated number of U.S. workers currently
exposed to beryllium is 134,000 [Henneberger, et al. 2004] and the total number ever
exposed is 800,000 [Infante and Newman 2004] however, these are likely
underestimates [Samuel and Maier 2008].
The nuclear weapons industry has received substantial attention because of
worker exposure to beryllium. In fact, beryllium disease was recognized among workers
involved in the early development of atomic energy in the World War II era [Hardy 1955,
Van Orsdstrand, et al. 1945]. As nuclear weapons proliferated during the Cold War, the
number of workers in the U.S. Department of Energy (DOE) nuclear complex grew and
the number of workers exposed to beryllium grew proportionately. Beginning in the late
1980s, clusters of CBD were recognized in workers from nuclear weapons plants across
the U.S. [Kreiss, et al. 1989]. Additional epidemiologic studies of nuclear workers have
been completed over the past two decades helping us to understand the risk of CBD in
this population [Kreiss, et al. 1993, Stange, et al. 1996a, Stange, et al. 1996b, Stange,
et al. 2001, Sackett, et al. 2004, Welch, et al. 2004, Rodrigues, et al. 2008, Arjomandi,
et al. 2010, Mikulski, et al. 2011]. These studies and others were chronicled in the DOE
Chronic Beryllium Disease Prevention Program (CBDPP), a regulation that was
promulgated to help prevent CBD in the DOE Complex [Department of Energy 1999].
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The National Research Council [2007] recognized that the diagnosis of BeS or
CBD may be associated with psychosocial stress and/or loss of income and that there
was an absence of published data on those phenomena. The NRC further suggested
that implementation of a comprehensive beryllium-exposure and disease management
program that includes appropriate worker education and counseling, medical-removal,
and protection against lost wages can minimize such potential adverse consequences
[National Research Council 2008].
Since psychosocial stress may be part of the disease experience, it is important
to understand the nature and extent of the psychosocial effects so that appropriate
interventions can be implemented. Substantial resources are already being invested in
educational programs, support groups, counseling, financial compensation, etc. to
reduce the impact of CBD on workers and their families [Departmetn of Energy 2011a,
Department of Energy 2011b]. These efforts are well-meaning but many do not have a
theoretical basis and are not supported by empirical data. That makes it difficult, if not
impossible, to evaluate the effectiveness of these programs.

Methods
The study participants were current and retired workers who had been diagnosed
with CBD or BeS and work (or worked) at one or more DOE facilities in Oak Ridge, TN.
They were recruited through the Beryllium Support Group of Oak Ridge (BSGOR). The
BSGOR is an education and advocacy forum for current and retired workers who have
either BeS or CBD. The Group is sanctioned and supported by the Y-12 National
Security Complex (Y-12). The Group meets twice monthly and provides educational
speakers and topical discussions. A presentation was made to approximately 60
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members of the BSGOR and 13 of those volunteered to be interviewed. The interviews
were conducted over a four month period.
Two key advisors from the study population provided feedback on the study
design. Both were current workers who had been diagnosed with CBD and were active
in the BSGOR. They provided feedback on the informed consent statement, the
interview protocol, written questionnaires, and recruitment methods. Adjustments were
made based on their knowledge and feedback.
Semi-structured interviews were held at either the participant’s home or at the
New Hope Center, a building at Y-12 with small, private meeting rooms that were
available to the public. Interviews lasted from 1-3 hours and were held over 1-2
sessions. An interview script was used to help guide the interviews. The interviews
were recorded and the audio files transcribed into text documents. The documents
were de-identified to maintain confidentiality and reviewed by an authorized derivative
classifier/review officer to ensure no classified information was revealed.
The documents were imported into QDA Miner 4 (Provalis Research
Corporation). Each case was assigned a unique identifier and 14 demographic
variables were recorded. A two-level coding manual was developed to aid in the
analysis of the qualitative data. Socially constructed (SC) codes were created based on
a theoretical model of the psychosocial effects of CBD [Miller 2012].
The model is based on three prominent psychological theories: 1) health, stress,
and coping, 2) uncertainty and illness, and 3) psychosocial adjustment to illness. The
model supports the hypothesis that workers who are diagnosed with BeS or CBD
experience a great deal of uncertainty and that has a detrimental effect on their health
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status. The focal relationship in this model is between the independent variable
uncertainty (i.e., the characteristic being observed) and the dependent variable health
status (i.e., the outcome of interest). It is hypothesized that the relationship between
these two variables may be partially mediated by an intermediate variable, the ability to
make psychosocial adjustments to disease. The model is illustrated in Figure 2.I.
The SC codes were based on the domains of each of the theories, as listed in
the model. Interview questions were structured to probe feelings, thoughts, and
experiences about each of these domains as well as to identify key events related to the
participants’ CBD experience.
The University of Tennessee and DOE Institutional Review Boards approved this
study. Participants signed informed consent agreements.

Results
Study Population
The study population consisted of individuals who were either working at or were
retired from one or more of the DOE Facilities in Oak Ridge, TN: Y-12, Oak Ridge
National Laboratory and K-25 Gaseous Diffusion Plant/East Tennessee Technology
Park. All of the study participants spent the majority of their careers at Y-12. The
participants were predominately white, male, craft workers in their late fifties. Most
(9/13, 69%) were still working and had been diagnosed with CBD (9/13, 69%). All of the
current workers were members of a Labor Union. A description of the study population
is provided in Table 2.I.
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Controlling Variables
(Potential Confounders)
•
•
•
•
•
•

Antecedents
•
•
•
•
•

Genetic susceptibility
Exposure
Sensitization
Symptoms of disease
CBD diagnosis
Independent Variables
(Uncertainty)
•
•
•
•
•
•

Focal
Relationship

Ambiguity
Inconsistency
Vagueness
Unpredictability
Lack of information
Unfamiliarity
Intermediate Variables - Mediator
(Psychosocial Adjustment)
•
•
•
•
•
•
•

Exclusionary
Strategy

Age
Education
Socioeconomic status
Vocation
Marital Status
Healthcare experiences

Healthcare orientation
Vocational environment
Domestic environment
Sexual relationships
Extended family relationships
Social Environment
Psychological distress

Dependent Variables
(Health Quality of Life)
•
•
•
•
•
•
•
•

Vitality
Physical functioning
Bodily pain
General health perceptions
Physical role functioning
Emotional role functioning
Social role functioning
Mental health

Inclusionary
Strategy

Figure 2.1. Socially constructed model of the psychosocial effects of chronic beryllium
disease
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Table 2.1. Descriptive statistics for the study population
Variable
Number of participants
Region of residence
Age

Gender
Marital status
Race
Education
Household income

Work status
Place of work

Job title

Disease status
Number of years sensitized

Number of years with CBD

Description
13
East Tennessee
Range = 51-85
Median = 59
Mean = 62.4
Male = 11
Female = 2
Married = 11
Divorced = 2
White = 10
African American = 3
Some college = 12
Associates Degree = 1
$25-50K = 3
$50-75K = 3
$75-100K = 4
>$100K = 3
Working = 9
Retired = 4
Y-12 = 9
Y-12 and X-10 = 1
Y-12 and K-25 = 1
Y-12 and X-10 and K-25 = 2
Administration = 1
Chemical operator = 1
Machine maintenance = 1
Machinist = 3
Maintenance craft = 5
Maintenance laborer/janitor = 1
Material control = 1
CBD = 9
BeS = 4
Range = 0-7
Median = 1
Mean = 2
Range = 3-19
Median = 8
Mean = 9
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Health Status
The health status of the participants varied widely, as would be expected in a
group that had experienced the full spectrum of CBD. Those who were BeS reported a
heightened awareness of their respiratory health but were largely asymptomatic.
Participant 9 (P9): I don't see that I have any significant problems or
anything. I can tell maybe that I am getting a little short of breath, but it
seems like, being diagnosed as being sensitive, any little thing that I've
read on the internet or something that might be a symptom, you're like,
well could that be because of that, whereas before I probably wouldn't
have thought anything about it.
Others with CBD who were in the early stages of disease reported some mild
symptoms but they considered their health to be good overall.
P4: You know I'm feeling good. The only problem I've had that I've noticed
since I was diagnosed is real hot weather. I have a little more problem as
far as breathing goes. But you know, in general, I feel good. I don't obsess
with it, and so I just keep on going.
Others were in the more advanced stages of CBD and reported more symptoms
and limitations related to their health.
P2: My health is okay. I use two inhalers a day because I do have some
shortness of breath, I have like other people, my night sweats, my joint
pain, I have insomnia pretty bad and it comes from having some pain that
comes into my joints and it makes it hard for me to sleep. Other than using
the inhalers just in case you get short winded. I think I'm doing alright. It's
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about the same from a year ago. It's worse than it was 5 years ago. Where
it used to be I didn't have any problem getting out, cutting my yard or
going up and down the steps or anything like that to where I may get a
little more winded now than I did.
Others reported other chronic conditions in addition to CBD. In general, they
indicated that their health was poor and that they had some significant limitations
because of their health.
P7: My health's in pretty bad shape, I have a lot of trouble, it seems like
I'm always hurting in my chest, my left lung, especially, And there's been a
couple times that, well more than twice, that I'll wake up, my CPAP
(continuous positive air pressure – a device used to treat sleep apnea)
was torn up, and I didn't have it, and I woke up in the morning and I
couldn't breathe, and this has happened several times. I just can't get my
breath and it's almost like, well I am, I'm smothering. I can't get my breath.
There were three key events that framed each participant’s experience with CBD:
occupational exposure to beryllium, diagnosis of BeS, and diagnosis of CBD. The timing
of these medically important events carried widely among participants. Once they
occurred, they triggered other sociologic events. Figure 2.2 provides a composite
timeline for these medical and sociologic events.
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Figure32.2. Key medical and sociological events related to chronic beryllium disease
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Occupational Exposure to Beryllium
The participants had very different experiences with beryllium exposure and two
patterns emerged from the data: some had direct exposure to beryllium as a part of
their daily job (e.g., machinist) while others had only indirect, incidental exposure (e.g.,
electrician). For some, frequent, direct exposure to beryllium occurred from the
beginning of their employment.
P3: The first week at Y-12 I began working in the machine shop; which
was the primary production beryllium shop at the time. We also worked
with a number of other materials but it was primarily beryllium in several
forms.
Others had infrequent, but still direct, contact with beryllium. One participant
could recall only a single incident where he had direct contact with beryllium.
P9: can only remember one time, I had maybe one little brief encounter
with some beryllium metal. We were using a grinder to grind some on a
lathe but we were flooding it with coolant and we had a vacuum hood over
it and everything. And I worked on it maybe one shift so I didn't see really
it was a big deal.
Others did not perform any work directly with beryllium but had indirect exposure
when performing their job. Those with indirect exposure were often un-informed of the
hazards of beryllium and ill-prepared to protect themselves. One electrician described
his indirect exposure to beryllium:
P7: In 1989 I started working on the roof of a building and we had the
exhaust fans, and that was one of my jobs, checking the exhaust fans. I'd
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go up on the roof and I would check on the fans, and I didn't know what
things was coming out of each stack. But beryllium was one of them.
Those with indirect exposure also seemed to have been provided with the least
information about the hazards of beryllium and methods for personal protection.
P1: I remember spending the summer in a building inside the plant,
working construction, and we were renovating that machine shop to
convert it to offices. We worked the whole summer in there. At the end of
the summer, I can remember the sprinkler contractor coming in and they
were going to put the sprinkler heads in. They were getting ready to do
that and they put moon suits on, and I said ‘Whoa-whoa-whoa, what are
y’all doing?’ They said ‘This is a beryllium machine shop!’ My response to
them was, ‘what's beryllium?’ I had no clue. We had no protection. If we
had gloves it was because we bought them ourselves. So I spent the
entire summer in there doing that. I have chronic beryllium disease, and I
know positively (taps finger vigorously on table for emphasis) that's the
building I got it in.
Over the past 15 years, the requirements for personal protective equipment and
housekeeping have changed to reduce the potential for exposure. Some participants
reported the effects of those regulatory and procedural changes.
P9: But you know everything is a lot cleaner now than it was back then. I
can see that in the shops now, the way they handle whatever it is you're
working with,” and “We were always protected, always wore respirators
and the right suits and everything by the book,” and “Well, everybody
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dreads it. It's just different now than it was when I first started wearing a
respirator. But I wear one pretty much every day that we've got a job. Most
of our jobs are dirty, contaminated areas. As a pipefitter, it goes with the
territory. If you're going to work in a nuclear place, it's pretty crappy
conditions usually,” and finally “Well there was a system set up where you
would come into one area you would take your clothes off and leave them
and go through a shower and go on home. So we was doing that but yet
the supervision and a lot of the secretary type people in the area did not
have to do that.
Diagnosis of BeS
There were two BeS patterns among the participants. Some were diagnosed
with BeS and CBD at virtually the same time; while others were BeS and had (or are in)
the latency period that precedes CBD. All of the participants found out they were BeS
by participating in medical screening programs that are part of the DOE current and
former worker surveillance programs. One screening program is affiliated with the
Atomic Trades Labor Council.
P1: I decided to come out here and go through the Atomic Trades Labor
Council medical screening. Great physical; best physical I've ever had. I
went through that and immediately found out I was beryllium sensitive. So
I went to see a specialist and he said ‘Well, yeah you're beryllium
sensitive’ and he said ‘The only way I can find out if you have the disease
is to do a biopsy.’ And I said ‘Well, then do it, ‘cause if I've got something I
want to know it.
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Others found out through the routine annual physical provided through the Y-12
Occupational Health Services Department.
P5: I was a beryllium worker at one point and I went for my physical. Every
year we were able to get physicals and I requested to have the LPT test
done. That's when I received notice. It came back, and I was called to
medical and they informed me that I had been exposed and that I was
sensitive.
Three of the participants had virtually no time lag between their BeS diagnosis
and their CBD diagnosis. This occurred in older participants who were first screened
many years after their first exposure. The majority of workers (9/13, 69%) either had
experienced or were in a latency period between BeS and CBD. One participant
suspected he had been sensitized for a while and it was only discovered when he
started experiencing respiratory symptoms.
P1: They did a biopsy, and within a month I've got chronic beryllium
disease. So I went from sensitive to disease within a couple of months,
which kicked my butt. Well see, I probably was beryllium sensitive for 15
years without knowing it. It's only when I finally decided to take the test
that I found out I was sensitive, and then I immediately had beryllium
disease.
Some (3/12, 23%) experienced the inconsistency that sometimes occurs with the
BeLPT. Their results alternated between normal and abnormal.
P10: So I went down there and took a test, a couple days later they called
me and said well I think our machines may have malfunctioned; we didn't
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get a good reading so we're going to do it again. They always tell you that.
So I went and did it again and found out I was sensitive. I didn't know what
in the crap they were talking about. I said what does that mean?
Diagnosis of CBD
Most of the participants with CBD (9/13, 69%) reported receiving a medical workup to establish whether their condition met the case definition for CBD.
P2: Well I had my first test (BeLPT) in June of '97 then came back in
October and said that they needed to do another one and then after that
they said that I needed to go to Vanderbilt and had to see a doctor down
there and they was going to do a lavage to see exactly what it was. That
was in January of '98 and then in February they called me back and told
me that I do have the disease. So it was within a 7 month period.
The lack of an abnormal BeLPT was problematic for two of the participants. Both
of them reported that they were told that their use of Prednisone was likely interfering
with the BeLPT.
P3: I had very high numbers in the lung lavage. Of course, being
symptomatic, they were putting the numbers, the lab work, the symptoms
and the history all together, it was pretty much a no brainer and I was
diagnosed with CBD right off the bat. But I had one LPT before actually
being diagnosed and I wasn't deemed as being sensitized because it was
barely below the cutoff. As I learned later, there's a one in four chance of
getting a normal when it should be abnormal under the best of, of
conditions. I don't remember what medicines I was on at the time, but
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prednisone will definitely mask a LPT so you know, you've got at least a
one in four chance of getting a wrong reading. You know, getting a
negative when it should have been a positive to begin with.
One participant had a diagnosis of sarcoidosis for 14 years that was later
changed to CBD. Repeated BeLPT tests were normal or borderline before an abnormal
result was obtained to help differentiate the diagnoses of CBD from sarcoidosis.
P6: I actually went through the worst symptoms that people have. I was
sick all the time. My pulmonary doctor, he said you know I really don't
understand it. And plus we didn't think anything else about it. Because he
didn't really know a lot about it, he knew a lot about sarcoid and
sarcoidosis but he didn't know anything about CBD. So I'm just thinking
that because people don't know, even physicians, it probably really was
CBD all along.
The Beryllium Bureaucracy
Every participant described frequent and often frustrating encounters with what
was termed the “beryllium bureaucracy.” These are the requirements, processes, and
systems that have been designed and implemented to provide medical care and
compensation for workers in the DOE who develop CBD and to provide preventive
measures so that today’s beryllium workers have a lower risk of developing disease.
Three prominent domains to the bureaucracy were identified by the participants: The
Department of Labor (DOL), Workers Compensation Insurance (Workers Comp), and
the Chronic Beryllium Disease Worker Protection Program (CBDPP). Each domain
intersects with the other in a complex web of rules and regulations that involve current
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workers, retirees, health care providers, employers, insurance carriers, the Federal
government, and State government. Figure 2.3 illustrates the interconnections of the
beryllium bureaucracy that vary depending on a worker’s employment and disease
status.
One clear pattern emerged from the data; the experiences of participants
changed dramatically with the passage of the Energy Employees Occupational Illness
Compensation Act of 2000 (EEOICPA) [2000] and the promulgation of the DOE Chronic
Beryllium Disease Prevention Program Final Rule in 1999 [Energy 1999].
The EEOICPA required implementation of a program to provide compensation to
employees of DOE, its predecessor Agencies, and its contractors and subcontractors
involved in nuclear weapons production and testing programs that develop an
occupation-related illness. Adjudication of issues pertaining to all claims for benefits
under the EEOICPA is the responsibility of the DOL.
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Current DOE
Workers

Chronic Beryllium
Disease Prevention
Program

Workers
Compensation
System

DOE Workers
with BeS
DOE Retirees
with BeS

DOE Retirees
with CBD
DOE Workers
diagnosed with
CBD after they
retire
Energy Employees
Occupational Illness
Compensation
Program (DOL)

DOE Workers
diagnosed with
CBD while they
are employed

DOE Workers
diagnosed with
other work
related diseases

Figure42.3. Intersections of the beryllium bureaucracy
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Part B of the EEIOCPA was implemented in 2001 to cover current and former
workers who have been diagnosed with cancers, beryllium disease, or silicosis and
whose illness was caused by exposure to radiation, beryllium, or silica at a covered
facility. Individuals or their survivors found eligible under part B may receive a lumpsum compensation payment of $150,000 and medical expenses for their covered
condition [EEOICPA 2000].
Workers Compensation insurance is a mandatory, no-fault system to provide
benefits for workers that become sick or injured on the job. It is regulated by state law
and covers most employees, not just those in the DOE [Annotated Tennessee Code
2012]. Large employers often are self-insured for Workers Compensation. Participants
who were diagnosed prior to 2001 dealt exclusively with the Workers Comp system.
P3: When I was first diagnosed, I was still working at the time, and since
it's a work-related illness, it's covered by worker's comp. But the Plant
itself is self-insured, so instead of the paperwork being filed through the
state of Tennessee as it is with a lot of companies, the Plant handles its
own Workers Comp. But it has to follow Tennessee State law. So, as I
said, I was diagnosed before the DOL program came into existence. So I
was covered early on by Workers Comp and worker's comp gives you a
choice of three doctors. The Company picks the list of doctors and then
you pick one from that list. With Workers Comp pretty much everything
that is justifiable to be work related is covered a hundred percent. That's
the good thing. The bad thing is it's an insurance company and they balk
at a lot of things.
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Insurance coverage for participants was a combination of coverage through
Workers Comp, the EEOICPA administered by the DOL, individual healthcare
insurance, and Medicare. The applicable coverage was determined by their
employment status (employed or retired), their age (for Medicare), and the status of
their disease (BeS or CBD diagnosis). Participants were in varying stages of the claims
process, depending on their disease status. The results of the interviews provided a
glimpse into the complexity of the two systems and the conflicts that the participants
experienced as they sought compensation for their work-related disease.
The CBPDD was created to: reduce the number of workers currently exposed to
beryllium at DOE facilities managed by DOE or its contractors; minimize the levels of
and potential for exposure to beryllium; establish medical surveillance requirements to
ensure early detection of disease; and improve the state of information regarding CBD
and BeS. It prescribed beryllium operation controls, reduced exposure limits, and
medical surveillance requirements that are enforced throughout the DOE complex
[Energy 1999].
Navigating through the bureaucracies appeared to be more difficult for those
participants who were diagnosed in the 1990s, before the passage of the EEOICPA and
CBDPP. Participants more recently diagnosed described fewer problems with the
Beryllium Bureaucracy. Clearly, individuals in the 1990s blazed the trail and in some
instances help establish a system that was simpler to navigate.
Workers Compensation System
One pattern that emerged when interviewing participants about their experience
with the Workers Comp System was a conflict between treating physicians. There was

78

often a conflict between the DOL and Workers Comp doctors and the participants were
forced to choose one over the other. This sometimes put participants in a position of
leaving the care of a doctor who they liked and trusted (their DOL doctor) in order to
maintain their Workers Comp claim. They could see either their DOL or Workers Comp
doctor, but not both.
P2: I've had some problems. One of the problems that we all have had is
the Plant picks the doctors on the (Workers Comp) panel that you go to.
Well the doctors on the panel don't agree with them being your doctor and
you having one under the Department of Labor also. They don't see why
you need two, and one of the reasons that we try to tell them is the
Department of Labor is saying that whatever doctor you go to with them
has to be your primary doctor. Department of Labor wants them to be the
primary doctor that you go to, but Workers Comp is saying that they’ve got
to be the primary doctor. There's a struggle, they both want to be the
primary doctor.

P10: Well see people are getting in trouble. I was going to (DOL
Pulmonologist) and then my Workers Comp doctor said look here, this
ain't going to happen. He chewed me out three times. He said I'm not
going to treat you if you're going to another doctor, getting medicine from
him that may counteract some of the medicine that I'm going to give you,
and then we're going to have a bad problem. He said either you stop going
to him or you stop going to me. So I quit going to (DOL Pulmonologist). I
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said well you're going to be my Workers Comp doctor, so I really need you
more than I need him. Well another guy out here at the Plant had the
same situation as me, had the same two doctors. He wouldn't drop his
DOL doctor, so he (the Workers Comp Doctor) dropped him. He said you
need to find you another Workers Comp doctor because I'm not going to
treat you anymore.

P1: I don't really know that I understand, to me it's gotta be a personality
thing. They just don't want somebody second guessing 'em. I never had a
problem with my heart surgeon and my cardiologist, they're both heart
doctors, they worked as a team. I don't know why, these people can't work
as a team. The conflict is between them and we're caught in between.
A second pattern that emerged was the sometimes adversarial nature of the
Workers Comp claim.
P3: You know, I understand from a Workers Comp point of view, that their
goal is, supposedly, to give the best treatment for the lowest cost. But we
don't always see that in action. We have the perception that they don't
have our best interests at heart.

P1: Workers Comp makes you feel like you did something stupid and they
have to pay for your stupidity. I'm fairly new to this process and I'm
already seeing it. Workers Comp gave me an oxygenator for at night at
home and when I was going on a trip I asked for a portable one and they
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said no you can do without. The Department of Labor said no problem;
here's a prescription. It’s puzzling to me why they would say you're gonna
be gone a week and you don't need oxygen even though it really makes
you feel better. That really pissed me off.

P3: We butted heads with Workers Comp people quite a bit. The doctors
did, especially.

P2: Okay when you go through the Department of Labor and you've
already went to National Jewish or to Cleveland Institute and they
diagnosed you with the disease (CBD) and now the Workers Comp doctor
is saying you don't have the disease. It’s creating a problem. Does that
mean that we don't get the benefits of Workers Comp? My feelings on it is
that the Workers Comp doctor needs to work with the Department of
Labor doctor instead of putting the stress on the person and telling them
that no you don't have the disease even though three other doctors say
you do. Don’t be sayin’ I'm the doctor for the company and the company is
saying that you don't have it even though the Department of Labor is
saying that you do.
Workers Comp benefits also do not cover BeS while the DOL program does.
This possibly delays treatment for some people with BeS because it was not covered
under Workers Comp.
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P3: Workers Comp does not cover beryllium sensitization. In my opinion it
should, because especially in 10CFR850 it states that even though it's a
precursor, it is an occupational illness. But the Company is saying that the
state of Tennessee does not recognize it as an illness so you're not
covered by Workers Comp until you're diagnosed with CBD. Most
coverage is denied under Workers Comp if you're only sensitized. The
thing about it is, most people that are sensitized have CBD, it just hasn't
been proved yet.

P2: I think as far as people working in the Plant once a person is
diagnosed as sensitized they ought to have the same right that a person
that got the disease has as far as going to pulmonary rehab because the
people that are sensitized a lot of time it's just that the doctor hasn't been
able to identify it yet. They are having the joint pain, the night sweats, that
headache, the heart palpitations. Everything that people with the disease
are having they are having. So I think that the Plant needs to be more
proactive for people that are sensitized and give them the chance to start
rehab as soon as they find out.
Some participants questioned the knowledge and experience of the Workers
Comp doctors in relation to CBD.
P2: The rest of them said that they would learn as they go because
treating berylliosis was the same as treating COPD, and that's what each
one of them would tell us. Now some of the doctors that they are putting
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on the Workers Comp panel are saying that they don't have time to go to
seminars or anything like that but from patients they will learn.

P1: mean three or four different sets of physicians all agreed I have
berylliosis and the Workers Comp doctor said naw, gotta be asthma. They
don't know what they're talking about. So it's really agitating to the patient
to have to fight the Workers Comp doctor when you've got a panel of
physicians saying we agree; you are sick.
The Workers Comp System evaluates impairment using a Maximum Medical
Improvement (MMI) rating. This process caused consternation for some participants.
P10: They talk about that MMI crap. My MMI was before I ever got CBD.
That's set up for like a broken bone or broken leg or something. You know
this is as good as it's going to get. For chronic disease it's pitiful. The best
you ever gonna be is before you ever got that crap. Well that's what they
use to send you back to work. Like if you get hurt on the job, break your
arm or something like that, they say okay he's at MMI he can go back to
work. So what are they gonna do for us that's got CBD, we're never going
to be at MMI, there is no MMI for us. They're still living in the stone ages.
One participant who was recently diagnosed with CBD reported no problems with
the Workers Comp system and in fact saw cooperation between the two systems.
P6: A lot of people have had problems but I did not. My Workers Comp
doctor, he's very good. I see him twice a year. And he said as long as I'm
not ill, I have my pulmonary function test, and he does an x-ray, he'll take
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blood. And same thing with my DOL doctor, they'll both do the same thing.
Here I come on board in 2010 and everything's just going along smooth
with both (DOL and Workers Comp). Yeah, nobody could believe it. I
mean everybody's just agreeing, going together and I'm not having any
problems.
Energy Employees Occupational Illness Compensation Act (EEOICPA)
In contrast to the Workers Comp system, the DOL administration of the
EEOICPA was viewed very favorably and the claims process was not difficult for most
participants. It appeared that today’s DOL process was improved over the process
when the Program first started.
P1: That program has been probably one of the best things that the
government has ever done to help the nuke workers. After I was
diagnosed with the disease they said, ‘Well you need to go over there to
the sick worker's program.’ I walked in. I'm looking around thinking ‘What
is this?’ The people over there are so helpful. You know I was upset when
I first came in, ‘cause that was like a day or so after I was told that you've
got this disease and I don't even know what it is. But you've got a disease
and I know I can't breathe, so it's got to be bad. So, they were real helpful.
Everybody over there, every single person I've ever met over there, is
empathetic, kind, courteous--the lady that runs it has got to be an angel.
And they really, they seem like they go out of their way to help.
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P1: It should not be, but Workers Comp is adversarial. The Department of
Labor, most of the time, feels like your family doctor trying to help you.

P9: I just called over there one day from work and set up an appointment.
Went over there, my time come and she called me back and took about
maybe an hour. Filled out some forms and she helped me with all that.
She helped me fill out those forms and stuff and then sent it off and it
came back and I didn't have a bit of a problem.

P8: It went real smooth. I'd already been through the other part, the cancer
part. But it went real good, they went right through, got my card, you know
I got the card in my pocket and I carry it everywhere I go. You know so it's
real smooth.

P4: The Department of Labor side of it was painless. I mean you know
when I was diagnosed with CBD I went down and filed a claim and it was
pretty much, just cut and dry. That was really easy.

P5: I just gave them some information that they asked for. And they more
or less just took it from there. It's a situation where they get the
information, send it to Jacksonville, and they either approve it or not. I
want to say it was this side of 6 or 8 weeks (to get approval).
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P2: I was thinking it was 2000. Once I put my paperwork in it took me 11
months from start to finish. But once it went through there wasn't any
problem. I got my card and under the program, started getting seen by the
doctors, so I don't have any problem with it. I think it works well.
Chronic Beryllium Disease Prevention Program (CBDPP)
The CBDPP affected those participants who were still in the workforce. All of the
current workers in the study population were witness to the changes that occurred in the
DOE Complex after the CBDPP regulation was established. There were mixed
emotions about the regulations. Some participants expressed disappointment that it
took too long for the protective measures to become law.
P1: They knew beryllium was a problem in 1930, but they didn’t address
those issues until they’ve got enough injuries, I call it a body count. Then
they address the health issues.
In contrast, others were more circumspect about past practices and the
difficulties of establishing new regulations and implementing programs to prevent CBD.
P4: I've always considered this a safe place to work, you know I really
have. And I think that the precautions were all we knew to do. We wore
respirators, but we weren't wearing respirators where they're wearing
them today. I honestly think that this Plant is doing everything they can to
mitigate the hazards of beryllium.
Some of the participants described how the requirements of the CBDPP had
directly impacted their work.
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P6: I had to go to medical and talk to them, and the doctor recommended
that anybody who was sensitive that the best thing to do is just not be
around it. So they tried to find places that people who are sensitive can go
where there’s no beryllium,” and “I can't go in a beryllium buffer area,
anything that's got a beryllium sign on it I'm out. So that's cost me a lot of
work and a lot of overtime jobs,” and “They have the signs up now, where
they didn't exist probably up until 2000. You're more aware of where
you're going. Make sure you're wearing the right PPE (personal protective
equipment). It makes you more aware of what's going on. Is there
anything in this room that could hurt me in any way;” and, “It's just different
now than it was when I first started wearing a respirator. But I wear one
pretty much every day that we've got a job. It's either a respirator or a
PAPR (Powered air purifying respirator) or fresh air (supplied air
respirator).
One participant described how senior management had enforced policies that
were designed to help those who develop BeS or CBD.
P8: When we first started these beryllium meetings now, I had a foreman
that didn't want me to come over here, we were busy. And I said well
whatever and I kind of let it go, and then after a while somebody said well
he's got to let you go I even heard one of the big wigs say it. He didn't
give me any lip at all after that. I said you heard the man, I think I'm going,
He said, well you go on now, if you want to go.
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There were situations where elements of the CBDPP had resulted in confusion
and caused some of the participants to worry about their long-term employment
prospects. For example, some participants expressed concern about the medical
removal protection benefits defined in the CBDPP.
P8: They start coming out with this stuff that you're on the clock, and they
may get rid of you. You know, they don't have to pay you after two years.
That's what come out here in the last few years. That puts me on the hot
seat, I gotta keep my job, but I also don't want to risk my life going back in
there. I even thought about going back in and going to talk to them again
about the possibility of getting back in again, because they were talking
about all this start your clock, even had their company lawyer out here to
talk to us, and the Doctor come out here and he was talking about it, and
he said nobody's going to lose anything. But according to the way the
rules read that once your clock starts, they only have to keep you going for
two years. I'm kind of in the middle of a big dilemma here on what I need
to do.
Some of the participants questioned some of the industrial hygiene methods
used to fulfill requirements of the CBDPP.
P9: One thing that I think I've kind of argued a little bit in years past, Y-12
I'm thinking is one of the only places around that does what they call the
dry smears. It seems obvious to me that you're going to get more with the
wet smear tests. Maybe they don't want to find beryllium over here in this
place. Or if you'd done the wet smear, you'd find the trace, you name it or
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something, where the dry smear's going to find it but it's going to be below
the limit or something.

P1: Over the years, two issues become very clear. Number one is the
rules change. The standards change. The second thing, which is probably
even more troubling, it's not as prevalent now as it used to be, it's the
bureaucracy. Well we really don't know that the stuff will hurt you, so go
ahead and work. They wipe test stuff; they check all kinds of hazards after
we do our work. That's what I call the bureaucracy.

P5: We have IH (Industrial Hygiene Department) come take smears and
we find it's there. And sometimes it's been over the limit so we're not sure
and that's been the thing that really bothers me. They'll come in and say
“well we've cleaned this area and we've cleaned that area and we're
gonna take smears so it's okay, we've cleaned them.” But it's not 100
percent because they'll go in it and they'll spot check places. So the areas
that you've cleaned, yeah that's fine but I can go in there and say “well
what about that area right there?” They go and take a swipe and the next
thing you know, it's over the limit.

Financial Stability
The results of these interviews indicated that the majority of participants (10/13,
77%) reported an annual income greater than $50,000 per year and 3/13 (23%)
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reported an annual income greater than $100,000. None of the participants reported
significant financial problems, such as bankruptcy due to their medical condition.
Several things appeared to positively contribute to the participants’ financial health.
The DOL Program provides for a lump sum benefit of $150,000 and up to
$250,000 for impairment for DOE workers that develop CBD and assures that they will
always have insurance coverage for the medical expenses related to CBD. This
contributed to the financial stability of some participants.
P3: Doctor bills, medicines, the breathing machine, everything has pretty
much been paid for. So there hasn't been a big financial loss because of
that.
Despite the obvious value of this benefit created by the EEOICPA, the settlement
created mixed emotions for the participants.
P2: Everyone would tell you that we feel there is that monetary gift they
give you because you got the disease that we feel our lives are worth a lot
more than that, but it's good that the government recognizes we were
exposed during the cold war days.

P4: You know the funniest thing that happens, at least for me, and I laugh
about it. You know people will come up and say, ‘Hey I heard you had
CBD.’ Yeah. ‘Did you get that money?’ I mean it's not that much money,
you guys! It's really sad to me that companies or government can buy you
for such little money. It's sad.
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P2: You get $150,000 once a person is diagnosed with the disease and
then they have impairment that you get $2,500 dollars per point of
impairment that the doctor gives you up to $250,000. The total amount
that you can get is $400,000 dollars. So then that person that gets the
$250,000 they’ve got 100% impairment, and if you've got 100%
impairment you can't do a lot; total oxygen and everything.

P8: I mean $150,000 ain't crap. It ain't really. It's enough to keep her (his
wife) going for a little while. Softens the blow a bit but it ain't enough to
where she can live forever. But I don't want it; don't want no part of it.
Because if I get it, it means I'm in trouble.

P1: I had a union rep tell me one time, ‘There would be a lot less people in
this valley that had chronic beryllium disease if there was no money
attached.’ Which, I'm thinking, how could you possibly think that, that
paltry amount of money for my lungs is why I have chronic beryllium
disease?
Uncertainty in Illness
The participants provided numerous examples of situations where they described
uncertainty that aligned with the domains of the MUIS. The MUIS has six primary
domains: 1) ambiguity, 2) inconsistency, 3) vagueness, 4) unpredictability, 5) lack of
information, and 6) unfamiliarity.
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When something is ambiguous it is open to more than one interpretation.
Participants shared several experiences that were ambiguous, the most prominent
being the results of the BeLPT. They described what it was like to receive a “borderline”
test result.
P3: I had the beryllium testing started in '92 and in retrospect, if I had
known what I was looking at my first blood LPT was borderline. I don't
remember the numbers, but it was something like a 2.8 on a 3 cutoff. That
may not have been the numbers but it was something along that line. If I
had known what I know now, I could look at that and been like, okay, that's
like being borderline pregnant.

P4: Well my first test was positive, and then they called me back up and I
had another one, and it was borderline. And then when I went to see my
doctor he said, “Okay, I want you to have another test.” Well I came back
here for another test and they wouldn't give it to me. So I tell him, I said,
“They won't give it to me.” And he said, “Okay well I'll give it to you.” So he
drew blood and it came back positive.

P5: One question that I've had and I still really don't understand because
when you say ‘borderline’ that, to me, that's telling me that you've been
exposed. And I don't know how they calculate it or whatever, but I know
there's some people where I work at right now that's borderline. They've
received three or four borderlines, and they have some of the same
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symptoms of people who are sensitized and with the disease but they
can't get medical benefit from the Department of Labor.
The ambiguity of a having a borderline BeLPT result is different than having two
or more test results that lack in agreement. That is, one test result was abnormal,
followed by a second test result that was normal, followed by a third test result that was
abnormal, etc. This is an example of inconsistency, the second domain in Uncertainty
in Illness theory. Some participants had experienced the erratic nature of the BeLPT
test results. One participant had an abnormal BeLPT that was followed by several
normal results.
P8: Well you had to make a decision if you wanted to stay in it or go out of
it, you know? It was your decision what to do. When it comes down to your
livelihood, I ain't for sure, you know they had a bunch of false positives, so
I didn't know if I had one or not, but I'm not going to take a chance on it. I
gotta keep my job, but I also don't want to risk my life going back in there.
Was it a false positive? ‘Cause I've had nothing but clean slates ever since
then.
Inconsistency was not limited to BeLPT results. There were other examples,
such as disagreement between doctors on the diagnosis.
P2: But what's happening with some of the doctors now is they want to go
back and run the lavage. They want to go back and do all the testing and
then on a couple of people they are telling them ‘no you don't have the
disease.’ Okay, when you go through the Department of Labor and you've
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already seen that Doctor and they say you’ve got the disease and now the
Workers Comp Doctor is saying you don't have the disease.
Some of the situations that the participants perceived to be inconsistent were the
result of changes in regulations and policies.
P4: I was back down in my area yesterday, first time in a long time. It's
kind of interesting to discover that a lot of the areas I had worked in with
just coveralls and now it's full dress out in respirators.
Vagueness means that something is not clearly understood or is not definitely
known. Participants described several situations where they experienced vagueness.
P6: Well I didn't like that feeling of not knowing, especially in the beginning
they were giving me like, ‘no it's not the sarcoid; I think you have an earnose-throat infection.’ I didn't like that because I'm sick, and they wanted
to blame it on anxiety, or having stress. I said you know my job was fine,
my home life was fine. I had no reason to be stressed. I told them they
were making me stressed because somebody needed to find out what
was wrong with me.

P1: Working in the Plant most people have the assumption that they're
exposed. There are hazards in the Plant. We call it ethyl-methyl-bad stuff.’
I mean when you take a look at the list when you go to the Sick Worker's
Program and you see a list of all these materials, they say “Have you been
exposed to these materials?” I put on all of them yes because it's very
difficult to say you haven't.
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P12: I've noticed it (shortness of breath) for a lot longer than I want to
admit. Because I just didn't want to admit that I'm getting older. Probably
about 45 actually I started feeling something. I assumed that it was just my
age that was doing that. I think that's what most people do that have this
problem.

P12: I don't have it, I don't think. I hope I don't. I'm sensitive, and that don't
mean jack squat really.

P7: I wake up about four or five times every night. Four minimum, and I
just don't know what causes it.

P4: I work with a guy right now that's had a positive LPT but he don't want
to know. He said, ‘I don't want to know.’ A lot of people are like that, they
don't want to know.

P3: I lived a reasonably healthy lifestyle. Why are these breathing
problems developing? My pulmonary doctor and I had a good working
relationship and he said we need to get to the bottom of this and find out
what caused this.
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P8: Well see when you hear cancer, it totally got my attention. When she
talked about beryllium you know, what, what are you talking about? And
you know what do you mean I'm sensitive? What does that involve?
You've not got the disease or nothing, with the other one, I knew I had it.
Ain't no I may get it, I already had it.
When something is unpredictable it is difficult or impossible to foretell or foresee.
The participants reported many instances where they had experienced unpredictability
related to their disease.
P5: Right now, I'm fine, I'm okay. And it could be like that, I mean, it could
never turn into CBD. But then there's always a possible chance that I can
get it and then that would be another conversation.

P5: Well, I would say the worst part is not knowing. People react different,
you know. I'm the type, I pray about it, and my faith is that everything is
going to be alright. So I mean I try not worry about the unexpected. But
yeah, you think about it.

P12: It's not that big of a deal to me right now (sensitization). But like I
said, you know things change when they tell you that you've got the full
blown berylliosis and then, then it seems like the clock's ticking. Up to that
point it's just, hey it ain't nothing ‘til they say you've got it.
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P3: My symptoms are all over the map, I'm having a good day today, I
didn't have a good day yesterday. Well I'm still wheezing some today but
that's still a good day. But, you know, we don't know what to expect.

P4: Of course we've had a lot of concern among people that have
beryllium disease or are beryllium sensitized out here that somehow it's
going to cost them their jobs.

P10: We (he and his doctor) ended up talking for about thirty minutes and
I was scared to death. I didn't know what was going to happen. I've always
heard that this could turn into cancer, and all that stuff.
Several participants described having a lack of information about the hazards of
beryllium or about the symptoms of disease. This seemed more prevalent when
participants described their experiences in the 1980s and ‘90s.
P4: You know, when I came here in '82 and we were given some asbestos
training but beryllium training didn't come till later. And I couldn't tell you
what the year was, but it was later.

P7: I knew several people that had it. And back then though it was kept
quiet, very quiet. I knew what I had, but I never had anybody talk about it.
So it was kept very quiet. After I was diagnosed, then they started
diagnosing all these other people that had it. Up until then it was kept very
quiet. You didn't hear any talk of berylliosis while I was working.
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P8: Back then I'd never heard of beryllium, didn't even know what it was.
You know when they told me I was a beryllium worker I didn't have a clue.
What? What are you talking about?
The final domain in Uncertainty in Illness theory is unfamiliarity. This refers to
situations that seem strange or that are not within one’s knowledge. Participants
offered some examples of unfamiliar situations that they had encountered.
P3: At the time that I received the information that I had CBD we didn't
have the network of informing people like we do now. I got my report from
the University of Pennsylvania, who did the testing, in a manila plant
envelope, at work on shop time and I had to root through it like, three
times before I really understood it. I mean, I didn't understand all the tests
that were done, I didn't understand what they meant, and it was pretty
overwhelming.

P12: I'm walking in like I just walked into a calculus class. I just got out of
general math okay, and y'alls talking calculus here and I don't even got a
clue. They're talking way over my head and I just kept coming down there
and finally I got to learn what they're talking about. Right at the first it was
like I was in a German class and I'm going, what'd they just say?

P3: I know I told my supervisor and a couple of coworkers. I'm not really
one to hold things in but still, I was confused myself and didn't really know
what all this meant. I didn't really talk about it to very many people initially.
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‘Cause you know who was I going to talk to? Like I said I didn't really know
where to go.

P4: Somebody explained it to me like, depending on where your
lymphocytes are in your body, you know lymphocytes go to where they're
needed in your body, and in my case it was my lungs. Like I said, I don't
understand all that.
Psychosocial Adjustment to Illness
During the interviews, participants described many situations that reflected their
ability or inability to adjust to their illness. Their situations were compared to the seven
principal domains of the PAIS [Derogatis 1986], all of which had been shown to have a
high relevancy for adjustment to medical illness. The domains include: 1) health care
orientation, 2) vocational empowerment, 3) domestic environment, 4) sexual
relationships, 5) extended family relationships, 6) social environment, and 7)
psychological distress.
The domain of healthcare orientation addresses the nature of the participant’s
health care posture and whether it will function to promote a positive or negative
adjustment to the illness and its treatment [Derogatis 1990]. Some participants were
highly engaged in their healthcare while others were less attentive.
P3: I've learned when I go to a doctor's appointment I take a list of my
medications, I do a daily vital signs chart, so I can see myself and show
the doctor is there a pattern to this? Is it worse certain times of year? I've
learned to take notes to the doctor. I mean if I just go in to the doctor and
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he says how's it going and I say everything's fine. He goes on to the next
patient. But if I've got my notes, say okay two weeks ago I had a really bad
attack and I bumped my Prednisone up 40 milligrams for three days, and
it's helped me organize better so far as taking care of myself.

P5: Being sensitive there's really not that much I can do right now. They
keep me monitored; every six months I go to my pulmonologist and he'll
do a CT scan or chest x-ray just to see how I'm doing. I keep up with it.

P8: I had (a doctor) and he passed away, so I just kind of let it slide for
about three years and then I went over here again just the other day, and
that new doctor, boy he just wants to help you do everything, he's too
helpful. This guy was setting me up for another scan you know, and he's
really taken a lot of interest in me. And it's like well alright, you know. So I
think I'm alright, but you know it makes you wonder.
Sometimes the spouse of the participant helped keep track of medical issues.
P1: (She) has the persistence to see the paperwork through. She makes
sure that I have files; you know a DOL file, a Workers Comp file, a
physician file. So she's, she's my paper pusher, my pill pusher, my record
keeper. I'm a good carpenter but that part of it I leave to her.
The vocational empowerment domain reflects the impact that a medical disorder
may have on vocational adjustment [Derogatis 1990]. The participants reported several
work-related circumstances that resulted from their diagnosis of BeS or CBD.
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Sometimes they were treated differently by their supervisor or co-workers because of
their disease:
P1: Some of it may be joking or kidding, but you never know with some of
the guys if it's really heartfelt. They just don't have the balls to come out
and say, ‘you don't have to do this dirty job because you can't wear a
respirator and I have to do it.’ When you can't suit up anymore because of
lung issues, you get the cushy jobs and they do the hard work. So yeah,
there's discrimination but you either allow it to consume you or you just roll
with it and keep going.
Co-workers were often curious and eager to learn more about CBD from the
participants. Sometimes their coworkers were concerned about the possibly that they
too might get CBD.
P2: I told them (coworkers). They were surprised because I was the first
one in the area where we were that had been diagnosed, and then it was
less than 6 months after I was diagnosed that this other fellow was
diagnosed with it. So everybody started wondering, am I next?
One participant said that sharing information with his co-workers was therapeutic
for him and helped him adjust to his disease
P10: Best I can remember nobody treated me any differently. A lot of
people asked me questions about it. It's kind of weird I guess, but I
enjoyed talking with people about it because it made me feel good and
hopefully gave them a little bit more education about it. My supervisor at

101

the time talked to me a whole lot about it, because he wanted to learn
about it (CBD).
Being diagnosed with BeS or CBD did restrict the job mobility of some of the
participants. Once they were diagnosed, they were not allowed to work in areas where
beryllium was present. This had a financial impact for some of the participants because
it limited their ability to work overtime and/or their participation in the Human Reliability
Program (HRP) for which there is a 10 percent wage premium.
P2: There are different jobs in my classification that pay more money that I
can't go to because of the area they are in, I am confined to one area and
if they said they didn't have any more jobs in there then I would be put on
a two-year clock to either retrain for something else or end up losing my
job. So it (CBD) restricts me to one area.

P8: The only thing that's good about working beryllium out here is you get
a lot of overtime. I'm missing the extra money that I would make from it,
but I decided I could do without it.

P9: I dropped out of HRP. It cost me 10 percent of my pay. Everybody
thought I was crazy, and I said well that 10 percent's not going to do me
much good if I’m sitting on a bed sucking on an oxygen bottle.
A frequent overtone from the participants was a sense of duty to try and prevent
others, especially younger workers, from getting BeS or CBD.
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P4: I don't guess it (CBD) made me feel any different about my work. You
know it just made me think, man we got to fix this, we got to prevent. Then
I got to thinking about the areas I worked in, you know I looked at all the
characterizations of the buildings and I thought, ‘Man, we're going to have
a lot of people, just not me, and the latency period is just catching up with
us.

P6: I think a lot of young people come in here, they don't know, they don't
understand. They're young and healthy; they think they're invincible. You
know that's how young people think. And I look at these young people and
I'll tell them if I see them, you don't know what you're doing to yourself,
follow procedure. Don't take a risk. You be careful.

P6: It's so much better than what it used to be. The problem is getting
people to follow the instructions and procedures. Now, they can say oh
well I don't need to, yes you do. If that job requires you to have a
respirator and a Tyvek™ suit, you need to wear that. But you've still got
people trying to cut corners. They're not worried about it because they're
not sick; they're not having any problems. And they are penalized I mean it
could even cost them their job. The workers have got to get it in their
mind. We have got to think safety.
The domain of the domestic environment is oriented toward illness-induced
difficulties that arise primarily in the home or family environment. It is designed to
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assess problems in adaptation experienced by the participant and their family unit in
response to the participant’s illness [Derogatis 1990]. Most of the participants (11/13,
85%) were married and most had adult children. They described how their condition
had impacted their spouse.
P7: It hasn't affected anybody except for my wife and me. It's affected her
quite a bit. I lay in bed at night and, it's kinda funny, but she'd reach over
and put her hand on me to make sure I'm still breathing.

P10: My wife's kind of wondering how worse am I gonna get. Am I going to
have to take care of you for the rest of your life? Yeah, I know she
stresses about that.

P9: The first one (abnormal BeLPT) I didn't say nothing to anybody. And
then the second one I did tell my wife, she’s a nurse. And she said, ‘what's
that?’ And I described to her what I thought it was and everything and she
was like, oh, okay. Probably about 2 months later, I seen a piece of paper
where she's scribbled about 10 or 12 things on it. She said you've been
having night sweats and every now and then you have a bump come up, a
sore place. She said, you've got slow wound healing. She went down the
list of 12 things and said you've got maybe 6 or 7 of them. At first when I
told her it was kind of over her head? But then she went on her own and
done this extra research.
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P8: My wife, she just calmed me down right off the bat. She went well
listen, you don't know you've got anything yet, it's just one (abnormal
BeLPT), we're going to do another one, see how it comes back.

P10: We've got all these DVD's that we made out here. My wife's never
watched them. I took them home and she's never wanted to watch them.
She said I just don't want to do that. I mean she's curious about it, she's
seen what it's done to me, how it's affected me but I don't think she wants
to get that emotionally tore up over it. Some of the scenes are pretty
graphic in those DVD's and they have people describing what it's done to
them and all it's done, and I don't think she wants to hear all that.
The participants also talked about the adjustments that they had made with their
partners. Some reported that their spouse also had severe health issues and this
sometimes helped them better appreciate what the other was experiencing.
P3: We know to cut each other slack because we understand, we
understand that there's going to be good days, there's going to be bad
days. There's going to be disappointments. We've planned on doing
things and had to cancel at the last minute because of me or her. It could
be either one.

P3: Any chronic disease, but CBD in particular, it does affect every
relationship you have and this is where I have tried to work on
communication skills to help the people that I'm involved with, whether it's
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children, significant other, friends, whatever. Help them understand the
impact that CBD has on me. Communicate back and forth, let them know
when I'm on high doses of medication and my moods might be through the
ceiling or below the floor. The Prednisone causes bad mood swings so it's
crucial that the people you're in contact with know what medications you're
on and what affect they can have and that, kind of like the old saying ‘it's
the whiskey talking, not me,’ and reserve the right to go back and say I'm
sorry. Because you probably will have some conflict because of that and I
think the communication is crucial.

P3: I know personally I have had, in the last 10 or 12 years, I have had
two relationships that failed, at least in part, because the other person
could not or would not cope with a potentially serious chronic illness. The
relationship that I'm in now, I'm involved with a lady that has a fairly severe
disability, so we understand each other a lot better than if one of us did not
have issues, have health issues.
When the participants told their children about their condition it sometimes
created fear and uncertainty for their children.
P1: You know daughters and fathers; Daddies are supposed to be bullet
proof. She's concerned. She's afraid. She's pissed. She's angry that I
have something that's wrong with me, that they gave me something.
Ultimately, she's the one that takes it the hardest. My son, if he sees me
impaired, not able to do something, he usually jumps in and helps. But,
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he's typical boy. He hides the emotions much better than my daughter. So
it's harder on them in a way than it is on me.

P6: I think it's bad for any kid to know that your parent is sick and that you
really don't know what's going on. My youngest son especially, well both
of them. You know, they were afraid. Is my dad going to die? It's questions
like that. I had to go through and explain everything that the doctor told
me. Even though he was like 18, he was still kind of afraid of the unknown,
not knowing. Since then, I say I’ve got to go to the doctor, they say,
“What's wrong? Is everything okay? Are you okay?”

P11: I have daughters. I've talked to them a little bit about it (BeS), when I
first got my diagnosis. (One said) “Well daddy what's that mean? You're
okay, aren't you?” and I said “‘yeah baby, I'm fine.” That was pretty much
it. But then there's always a possible chance that I can (get CBD), and
then that would be another conversation.
Some of the participants worried about the financial security of their family should
they become disabled and unable to work.
P8: As soon as I got home I told my wife about it. She said well what the
heck is that? I said it could affect me sometime down the road, but I'm
covered. I said the Department of Labor is going to cover me so if
anything happens you know we'll be alright. It comforts her a little bit
because I'm her sole source of money. If something happens to me you
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know she's in trouble. So it's something I really worry about, you know
making sure that the family's taken care of.
The domain of sexual relationships is designed to provide a measure of any
changes in the quality of sexual functioning or relationship associated with the
participant’s illness or sequelae of the illness [Derogatis 1990]. Some participants
described both physiological and psychological intimacy issues that they felt were
related to their disease and/or the medications they were taking.
P3: One point that I wanted to make was in the area of relationships
because it's really difficult to maintain a relationship when you've got a
chronic illness. I've seen several people, maybe it doesn't just apply to
CBD, but other chronic illnesses as well, where people just give up on a
relationship, I mean they give up on the possibility of a relationship
because they think nobody's going to want me because I'm damaged
goods, more or less. They deprive themselves of the possibility of a
relationship because of that.

P3: You know, personally speaking, I've had issues, and in fact that is one
of my covered conditions under Department of Labor. You know there's
treatment.

P9: My testosterone level was way low. He (his doctor) said it was about
nonexistent. And he said, have you noticed any problems, any sexual

108

problems? And I said yeah a little bit, I just thought I was getting old,
cholesterol and all that stuff too.

P3: I know people personally that have opened up and in the support
group that say “well we, my wife and I or my significant other and me, we
don't do anything intimate we don't do anything physical.” Nothing? You
know if you at least touch each other, a back rub beats nothing!
The domain of extended family relationships is devoted to measuring any
disruption or derangement in relationships with the extended family that arises with the
illness experience [Derogatis 1990]. Most participants described little to no discussion
about their condition with extended family members,
P10: It's hard to talk to people that don't work here. You have to go
through the whole deal of explaining what it is. You know my brother, I had
told him before that I had a disease, but it just never registered with him.
And then when he was down here last year I said something about it and
he must have forgot and he said what are you talking about? I said I have
an incurable disease that I contracted from work that could end up giving
me cancer or kill me or something. So then I guess he didn't know what
kind of questions to ask. Yeah, he just, kinda well looked at me real funny
and he didn't really know what to say.

P1: Family, they don't know what it is. They just know that you have a lung
issue, that you can't breathe good. But it's not too big of a deal, I've got
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two brothers on sleep apnea machines so they understand that part.” I
mean a lot of times they tell me I'm not supposed to do as much as I do,
but I'm gonna do what I do until I die.
The domain of social environment reflects the status of the participant’s current
social and leisure time activities and the degree to which the participant has suffered
impairment or constriction of these activities as a result of their illness [Derogatis 1990].
Most of the participants had made adjustments in their leisure activities based on their
degree of impairment.
P12: If you'd have asked me 10 years ago, what are you going to do for
retirement? I'd have said hunting and fishing, but that ain't going to
happen. I go and stay for three days and I'm good, come back home and
I'm glad to be home. Back ten years ago I'm going to hunt the whole
season, every day. Things change. Is this (BeS) making things change, or
is it just age?

P10: I went to Alaska last year on a cruise and that was great, the weather
up there was super good for me. Went to Seattle spent two days in
Seattle. Boy that was awesome. I felt great up there. But when I got back
here I could feel that humidity, whew!

P2: Really nobody outside of my wife really knows I got the disease. So it
hasn't created any problems when I go to church socials or anywhere
else. Nobody really knows that I'm using my inhaler or I'm struggling or
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anything like that. So it hasn't created any problems. I don't get out and
run with my grandkids the way I used to but I'm older of course. But I don't
do all of that and they don't know it's because my breathing has changed.
So outside of work, with family and friends they can't tell the difference.
The BSGOR became an important social network for most of the participants.
Participants described a variety of reasons why people attend and what keeps the
network functional
P3: The support group is like a lot of other groups, it rises and falls. I mean
sometimes there's really good attendance and sometimes there's just a
very, sprinkling of people that will attend. You have a few people who will
lead and do most of the work, and then you have some followers and then
you have people who drift in and out. But I know in my case my
involvement in the support group over the years was therapy.

P4: Well, you know, I mean, look, I've got beryllium disease, there's
nothing I can do to change it. Just go in there (to BSGOR meetings) and
listen to people go on and on and on. We call them berylliacs because
they are so obsessed with the whole thing, and I go come on, live your life.
You've got it, here it is. You know I'm a black and white type of person.
One participant described efforts to use social media to help people with BeS or
CBD connect and share information.
P3: It (beryllium group on Facebook®) hasn't had a lot of action, to tell the
truth. But the people that have got on there, you know they're just, just like
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people that come to the support group. They are trying to understand the
Department of Labor bill and how it applies to them and how to file claims.
It hasn't grown as I expected it to. But it is serving a purpose.
Other participants relied upon their faith and church to help them adjust to their
condition.
P6: Our faith has helped us to get over a lot of our fears. And I think that's
what's keeping us going. I mean right now, I don't think about it as much
as I did. Like I said when I first found out I had anxiety but it's been years
for me so I feel better about it now.

P9: Well guess it was probably a couple of weeks ago, we were talking at
church, me and the preacher and he stepped up to me real somber like
and said, ‘now how've you been doing?’ I was like, you talkin’ to me?
(laughing) I'm doing okay I think. ‘I mean how's your breathing?’ I was like
well I'm still okay I guess.

P5: Faith never really comes up. I've never heard somebody just come out
and say you know my faith in God is what keeps me going, helps me
through this. I don't live one day thinking about what can happen or will
happen. ‘Cause like I said, whatever's gonna be is gonna be.
The domain of psychological distress is designed to measure dysphoric thoughts
or feelings that accompany the participant’s disorder or are a direct result of the illness
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and its sequelae [Derogatis 1990]. Participants described a wide range of emotions
related to their diagnosis.
P1: When I first got it I was enraged. I was really pissed. I've had a lot of
stuff to deal with--been married twice, I've been through Vietnam; three
tours in Asia. I've had stress. I've had issues. But this kicked my ass,
because I would think back and say I know where I got this. There for a
while, I think mentally I was worse than I was physically.

P6: Well, when they first diagnosed me it was very terrifying.

P3: Being diagnosed with beryllium disease, that changes your attitude
about a lot of things. There were feelings of betrayal, of anger, you know
just a wave of depression. Like, okay, what does this mean? That's the big
question. I know I have this and I know I already have symptoms, how
much worse is it going to get? How long is it going to take? It's all these
unanswered questions that kind of, plug you at the same time.

P12: I'm tireder. I can breathe a little less. But hey I'm getting older, and
that's what I'm thinking up to this point. And then they tell you, yeah you're
sensitive and then you start having these anxiety type things, going this
may be for real. I may have what they say I got.
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P3: You know, in some ways it's almost a relief when you get the
diagnosis because at least now you have something. OK, this is the issue
and now we can go forward with how can we deal with it.
Some of the participants who were in an advanced state of disease described the
stress associated with the physical symptoms of CBD.
P1: I don't know that even my heart attack was as tunnel vision as the first
few times that I could not breathe. That is so acute, that absolutely you
don't think about anything. Even during the heart attack, I'd think about
something – my kids, my wife, all the work I hadn't done. But when you
can't breathe there's nothing on your mind except (gasps) you can't
breathe. It's…it's a, well for the lack of a better word, a terror.

P7: I woke up in the morning and I couldn't breathe, and this has
happened several times. I just can't get my breath. And it's almost like,
well I am, I'm smothering. I can't get my breath. When I get that, it does a
number on me.

P3: It's never a straight line with me. It's always a roller coaster, up and
down. When I have a bad day, when I'm having trouble breathing and
aching all over and man, it's not worth it. I have to convince myself that it
is. So it's, it's an ongoing battle.
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P3: You've got to learn your own body and learn that it's OK to backslide
sometimes because you're going to have bad days, bad weeks, maybe
bad months. And the hardest part is, you know when you do backslide it's
to get started back up again.

P9: A lot of people don't want to look at the end out there, but I don't really
have a problem with it. You don't want to leave anytime soon but I realize
my own mortality, which a lot of people have a big problem with that.
You're gonna leave this world for one reason or another. I could die of
prostate cancer or get killed in a car wreck, you know. So my faith I think
helps me with life in general, as far as stuff like that.
Others described the ill feelings that resulted from their encounters with the
beryllium bureaucracy.
P1: It's really agitating to the patient to have to fight the worker's comp
doctor when you've got a panel of physicians saying you are sick.

P1: It was a shock to find out that I had a disease that was work related
and that probably could have been prevented. And, you know, I… all
these emotions come in to play when you find out what caused your
condition. We pretty much believed what we were told. We believed that
we were working in a safe environment.
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P3: All these little pieces add up. You know the resentment toward the
company, the stress of wondering whether you're going to have your job
next week or next month, is my significant other going to understand this
and how much is this going to take off of my projected lifespan? I mean all
of these little pieces add up and it can lead to a major depression.

P4: Early on I went a lot (to Support Group meetings) and I felt like I would
go and I would listen and it was, it was kind of a woe is me pity party type
thing. And I just, I didn't need that. That didn't do it for me.

P7: I have nightmares about the Plant almost every night. I dream about
that place and I'm always trying to get from this place to that place and I
can't go because I can't get through the security part of it to get over there.
And it's just, like I said it's almost every night. One time I'll be on the back
road over there trying to get into another place and I can't go that way
because I can't get through the guard gate. And I can't get out and it's just
like that almost every night. I can always get in, but I can't get in certain
posts.

P11: I have such god-awful dreams you ever wanted to think about.
Sometimes they'll run for four or five days, and then I'll go without it.
Some of them were just being out there at work. And the people, some of
the people I knew. Things like that, especially at Y12, I don't know why at
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Y12. You know, we had to go through three checkpoints to get to work. I
know the people and was talking to them, just like we are talking now. I
don't know, it isn't all the time in the same way, it isn't all the time with my
night sweats.

P8: I never thought I'd ever get it, we always wore respirators when we got
around it. We always took precautions, so I always thought I was pretty
safe. You know, and all the sudden it was kind of a rude awakening when
she told me I was sensitized. That kind of shook me up. It did shake me
up a little bit.

P8: Well after I read all the paperwork, and listened to them guys, you
know, a few months of going over there I started realizing what it was all
about you know. And you see these guys, and you see them over the
years deteriorate, you know that's what strikes you, watching them
deteriorate.

Discussion and Conclusions
Do the qualitative data provided by the participants support the a priori model of
the psychosocial effects of CBD? First, is the question of whether the participants
reported uncertainty in a manner that was consistent with Mishel’s Uncertainty in Illness
Theory [1981]. In the model, uncertainty was proposed as an independent variable that
influenced health quality of life. The Michel Uncertainty in Illness Scale (MUIS) has six
primary domains all of which were presented in the results section: 1) ambiguity, 2)
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inconsistency, 3) vagueness, 4) unpredictability, 5) lack of information, and 6)
unfamiliarity. In studies examining the adjustment to uncertainty in illness [1990], the
most common conclusion was that high uncertainty was related to high emotional
distress, anxiety, depression, and fatigue.
The participants provided multiple examples of uncertainty resulting from their
BeS or CBD. These examples provided clear and specific examples that were
consistent with the definitions for each of the six domains of the Mishel Uncertainty in
Illness Theory. All of the domains were represented but the number of passages that
were coded to the unpredictability domain was greater than the other domains. This
suggests that for these participants, unpredictability may be the dominant feature of
uncertainty.
Second is the question of whether the participants described adjustment to
illness that was consistent with DeRogatis’ theory of Psychosocial Adjustment to Illness.
[Derogatis 1986]. This was proposed as an intermediate variable in the model. The
Psychosocial Adjustment to Illness theory reflects seven principal domains all of which
had been shown to have a high relevancy for adjustment to medical illness: 1) health
care orientation, 2) vocational empowerment, 3) domestic environment, 4) sexual
relationships, 5) extended family relationships, 6) social environment, and 7)
psychological distress.
The participants provided descriptions of how they and their family members had
adjusted to their illness. There were examples that were consistent with each of the
seven domains of the Psychosocial Adjustment to Illness theory. All of the domains
were represented but the number of passages that were coded to psychological distress
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was greater than the other domains. This suggests that for these participants, methods
for coping with psychological distress may have been more important than other
mediating factors. One factor that did not clearly fit into the Psychosocial Adjustment to
Illness model was financial security. The participants appeared to be in a moderately
secure financial position and this may have been an important mediating factor in their
adjustment to illness.
Based on the results of this study, it appears appropriate to apply Uncertainty in
Illness and Psychosocial Adjustment to Illness theories to beryllium sensitization and
chronic beryllium disease. Uncertainty may be considered an independent variable and
psychosocial adjustment an intermediate variable in the study of the psychosocial
effects of CBD. A quantitative study to measure the relationship between these
variables and health quality of life is underway. Those results will be reported in the
future.
All of the participants described key events related to their disease. Some of
these key events were part of the natural history of CBD (e.g., diagnosis) while other
events were sociological phenomena (e.g., filing a Workers Compensation claim).
Regardless of their origin, each of these key events was capable of producing a variety
of psychosocial effects. The chronology of these key events varied greatly among the
participants; some events could occur over a wide range of years (e.g., length of BeS
period) and certain events were predecessors for others (BeS diagnosis must precede
filing a DOL claim). The medical events (i.e., exposure, sensitization, diagnosis of CBD,
and disability) have been well documented in the literature but they have not been
reported in context with and linked to the other sociological events.
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While these key events were common to the participants, depending on the
progression of their disease, the circumstances surrounding how the events occurred
varied widely. For example, the participants who were the first to file Workers Comp
claims in the 1990s and DOL claims in the early 2000s reported a much more difficult
and frustrating experience than those that had filed claims within the last 2-3 years. The
psychosocial effect of these events appeared much greater for those participants that
blazed the trail for others behind them.
The first theme to emerge from the qualitative data – the CBD Trailblazers – was
based on these early experiences. There are several people that are often thought of
as medical pioneers who recognized the association between beryllium exposure and
disease. Some went on to conduct groundbreaking epidemiologic studies and discover
new diagnostic and testing methods that are used in today’s surveillance and treatment
protocols. What we have not recognized is that there have also been workers that have
had to navigate their way through an untested and often times ill-prepared bureaucracy
to receive treatment and just compensation for their incurable occupational illness.
These CBD Trailblazers were mostly craftsmen who were diagnosed with CBD and, out
of necessity, became vocal advocates for sick workers. They helped shape the laws
and regulations that are now in place to prevent CBD and to ease the burden on future
workers who are unfortunate enough to develop BeS or CBD. The CBD Trailblazers are
now tired and sick as they enter the later stages of CBD. Fortunately, there have been
others who have demonstrated a willingness to lead and assume responsibility for the
roles that the CBD Trailblazers fulfilled for many years.
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The second theme to emerge from the interviews was termed the CBD
rollercoaster. A rollercoaster ride was a metaphor used by one of the participants when
he described his experience with CBD, “it's always a rollercoaster.” His metaphor was
expanded and applied to the total CBD experience as described by the participants.
Because exposure to beryllium carries with it a lifetime risk of developing CBD,
this is a rollercoaster that one can get on but never get off. In years past, many people
did not know they were exposed to beryllium while today’s beryllium workers are trained
and informed of the risk on a regular basis. At least now, most workers have a choice
as to whether they wish to get on the CBD rollercoaster. The CBD Trailblazers did not
always have that choice.
At the outset, no one can predict with certainty the nature of the ride. For the
vast majority of people, there are no consequences to their exposure to beryllium. They
never develop any signs or symptoms of CBD and they go about their lives, the only
difference being that they retain some unquantifiable risk of developing CBD, a risk of
which they may not be aware. Their rollercoaster ride is tame; some workers may never
even know that they are on the ride.
Others, those considered beryllium workers, are in for a much different
experience; especially those who are genetically susceptible. Beginning with the
BeLPT testing, they may be jerked left and right, up and down, normal and abnormal.
Once they have a confirmed abnormal BeLPT, the rollercoaster enters a dark tunnel.
The darkness represents BeS and their inability to predict their future. They do not
know when the next turn or dip will occur. They are anxious and filled with uncertainty.
They don’t know how long they will be in the dark, only knowing that at some point they
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will emerge into the light. They are hyper-alert to changes in their body and when they
begin to experience symptoms they fear that they will be diagnosed with CBD. It is only
when they are diagnosed with CBD that they emerge from the darkness.
After diagnosis, the twists, turns, peaks and valleys of the CBD rollercoaster
become visible but not predictable. Symptoms wax and wane. One does not know how
long the climb will be nor how steep the descent. The speed with which symptoms
develop and the severity provide added terror. Workers Comp provides a corkscrew in
the track. The DOL absorbs some of the shock. The ride goes on forever. They get
paid to endure the ride; only wishing they could pay to get off.
It is important that we learn from those that have experienced BeS and CBD.
The participants in this study shared rich examples of how BeS and CBD had affected
them, their families, friends, and coworkers. Their knowledge can help healthcare
providers develop programs focused on the coping skills to manage the psychological
and social stress of BeS and CBD.
There are limitations to this study that must be considered when interpreting the
results. The small sample population may not be representative of the larger population
of individuals with BeS or CBD. Each of the participants attended at least some of the
BSGOR meetings. This may have had an effect on their disease experience and
influenced their responses. All of the participants were volunteers. Their motives for
volunteering may make them different from those who did not volunteer. Due to the
limitations of this study, inferences based on these results about the larger DOE
population or for beryllium workers in private industry may not be valid.
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Further research to understand the relationships between uncertainty,
psychosocial adjustment and health quality of life is needed. This would help validate
the proposed model of the psychosocial effects of BeS and CBD. Additional analysis
and modeling would be useful for learning which domains of psychosocial adjustment
are most important. This would be helpful for healthcare providers and support groups
that develop and deliver tertiary prevention programs to this population.
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Abstract
Background
Current and former workers from Department of Energy laboratories and manufacturing
facilities were surveyed to measure the psychosocial effects of beryllium sensitization
(BeS) and chronic beryllium disease (CBD).
Methods
Questionnaires were administered to measure uncertainty in illness, psychosocial
adjustment to illness, and health quality of life. Differences between mean scores were
tested, correlations between variables were measured and a multiple regression model
was developed. Results were compared to a model describing the psychosocial effects
of BeS and CBD.
Results
There were 126 participants; 52 with CBD and 74 with BeS. The health quality of life
survey indicated participants with CBD had significantly different physical component
summary scores than those with BeS. Mental component summary scores were not
significantly different. Psychosocial adjustment scores were significantly different.
Uncertainty scores were not significantly different. Moderate to strong correlations were
found between the three variables. A multiple regression model indicated that
psychological distress, social environment and domestic environment were the best
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predictors of mental component summary scores. As uncertainty increased, health
quality of life decreased unless the effects were mediated by psychosocial adjustments
to the illness.
Conclusions
The results added validity to the model of the psychosocial effects of BeS and
CBD. Uncertainty is an independent variable that influences health quality of life, the
dependent variable. Psychosocial adjustment is as an intermediate variable that
mediates the effects of uncertainty. BeS may have as much impact on mental health as
CBD. Psychosocial effects are an important component to the spectrum of CBD that
has implications for treatment and workers compensation.
Key Words
Chronic beryllium disease, berylliosis; beryllium sensitization; uncertainty in illness;
psychosocial adjustment; health quality of life
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Introduction
This is a report of a study of the psychosocial effects of beryllium sensitization
(BeS) and chronic beryllium disease (CBD). The aim of the study was to collect and
analyze empirical data to add validity to a proposed model of the psychosocial effects of
BeS and CBD and to aid in the design, implementation and evaluation of support
programs for workers with BeS or CBD and their families.
Beryllium is a strong, lightweight metal that is toxic when particles are inhaled
into the lungs. People who work in factories where beryllium is processed are
potentially exposed to beryllium particles and may develop an allergic reaction to the
metal. Some that become sensitized to beryllium go on to develop CBD, a severe and
incurable occupational lung disease.
Frequently reported symptoms of CBD include one or more of the following:
dyspnea on exertion, cough, fever, night sweats, and chest pain and, less frequently,
arthralgia, fatigue, weight loss, or appetite loss [Maier 2002]. On physical examination,
a health care provider may find signs such as rales, cyanosis, digital clubbing, or
lymphadenopathy. A radiograph of the lungs may show many small scars. Examination
of lung tissue under the microscope may show granulomas. Patients also may have an
abnormal pulmonary function test and when lymphocytes are cultured in the laboratory
in media containing beryllium they will exhibit abnormally rapid proliferation in a
specialized test called the peripheral blood beryllium-induced lymphocyte proliferation
test (BeLPT) [Samuel and Maier 2008]. CBD may be confused with other lung
diseases, especially sarcoidosis [Müller-Quernheim, et al. 2006, Infante and Newman
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2004]. In advanced cases, there may be manifestations of right-sided heart failure,
including cor pulmonale [Samuel and Maier 2008].
Epidemiologic studies have shown that a range of 1-6 percent of workers
exposed to beryllium develop BeS, although the rates can be as high as 19 percent
among workers with the highest exposures to particles or fumes, such as beryllium
machinists [Maier 2002, Kreiss, et al. 1993, Kreiss, et al. 1989, Kreiss, et al. 1997,
Kreiss, et al. 1996, Schuler, et al. 2008]. Most workers who are going to develop BeS
tend to do so early on, but follow-up testing over the years continues to identify workers
with BeS—up to 30 percent in one group of workers [Schuler, et al. 2008]. Continued
testing can reveal new sensitization many years after a worker stops working with
beryllium.
The percentage of people with BeS who go on to develop CBD is highly variable,
ranging from 10-100 percent in different worker populations [Kreiss, et al. 2007].
Individuals exposed to the highest levels of airborne beryllium dust are at greatest risk,
although skin exposure may also be important in the development of BeS [Day, et al.
2006]. Recent research suggests that each year, 6-8 percent of people with BeS will
develop CBD [Newman, et al. 2005a]. The latency for converting from BeS to CBD is
highly variable, ranging from 1-12 years in one longitudinal study [Newman, et al.
2005b]. Factors such as particle size, type of beryllium used, amount and duration of
exposure to beryllium, occupation, industry, and genetics all play a role in determining
why some people develop CBD and others do not [Maier 2002, Kreiss, et al. 2007].
Once a person is exposed to beryllium, he/she carries a lifelong risk of developing BeS

132

or CBD, even if the exposure amount was small or exposure has ended [Kreiss, et al.
2007].
Beryllium is widely used in the aerospace, electronics, biomedical, defense,
telecommunications and other industries [Jaskula 2011]. The estimated number of U.S.
workers currently exposed to beryllium is 134,000 [Henneberger, et al. 2004] and the
total number ever exposed is approximately 800,000 [Infante and Newman 2004]
however, these are likely underestimates [Samuel and Maier 2008].
The nuclear weapons industry has received substantial attention related to
worker exposures to beryllium. Beryllium disease was recognized among workers
involved in the early development of atomic energy in the World War II era [Hardy 1955,
Van Orsdstrand, et al. 1945]. As nuclear weapons proliferated during the Cold War, the
number of workers in the U.S. Department of Energy (DOE) nuclear complex grew and
the number of workers exposed to beryllium grew proportionately. Beginning in the late
1980s, clusters of CBD were recognized in workers from nuclear weapons plants across
the U.S. [Kreiss, et al. 1989]. Additional epidemiologic studies of nuclear workers have
been completed over the past two decades helping define the risk of CBD in this
population [Kreiss, et al. 1993, Stange, et al. 1996a, Stange, et al. 1996b, Stange, et al.
2001, Sackett, et al. 2004, Welch, et al. 2004, Rodrigues, et al. 2008, Arjomandi, et al.
2010, Mikulski, et al. 2011].
The National Research Council (NRC) [2007] recognized that the diagnosis of
BeS or CBD may be associated with psychosocial stress and/or loss of income and that
there was an absence of published data on those phenomena. The NRC further
suggested that implementation of a comprehensive beryllium-exposure and disease
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management program that includes appropriate worker education and counseling,
medical-removal, and protection against lost wages can minimize such potential
adverse consequences [National Research Council 2008]. If psychosocial distress is
part of the disease experience, it is important to understand the nature and extent of
these effects so that appropriate interventions can be developed and implemented.

Methods
The study population was drawn from current and former workers who had been
diagnosed as having either BeS or CBD and worked in the DOE Complex, a collection
of more than 20 large government-owned laboratories and manufacturing plants across
the U.S. The precise number of people in this population was unknown but was
estimated at 1167. This is likely an underestimate because the data from the two
nationwide systems for reporting cases of BeS and CBD, one for current workers and
one for former workers, are not coordinated and both systems have difficulty identifying
new cases of CBD. Table 3.I provides an estimate that was based on the best published
information from the DOE.
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Table 3.I. Estimated study population
Category

DOE Current
Workers
110,000
22,392

DOE Former
Workers
600,000
0

Estimated Total
Beryllium-Associated Worker Registry
Participants
Former Work Medical Surveillance
0
76,899
Participants
BeS Diagnosis
355
514
CBD Diagnosis
134
164a
Subtotal (BeS or CBD)
489
678
Total
1,167
Sources: [Department of Energy 2011a]; [Department of Energy 2011b]
a
=Estimated; DOE=Department of Energy; BeS=beryllium sensitization; CBD=chronic
beryllium disease

Convenience sampling was used to select participants for the study. Three
recruiting methods were used. First, presentations were made to the Beryllium Support
Group of Oak Ridge, TN (BSGOR). The BSGOR is an education and advocacy forum
for current and retired workers who have either BeS or CBD and their families. The
Group is sanctioned and supported by the Y-12 National Security Complex (Y-12), a
DOE manufacturing facility. The Group meets twice monthly and provides educational
speakers and topical discussions. Attendance ranges from 20-200 people per meeting.
Two presentations were made to the BSGOR about this study and informational
packets were provided to potential participants. Information packets contained a cover
letter, consent form, four different questionnaires, and a return envelope. An estimated
80 people were contacted via the BSGOR. Some of these participants consented to indepth interviews as part of a related qualitative study. Questionnaires were completed
by these participants before they were interviewed.
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Second, a mailing was made to current and former workers who were on the mail
distribution list maintained by the Y-12 Site Occupational Medical Director (SOMD). This
database consisted primarily of current and former workers who had been diagnosed
with BeS or CBD and worked at one or more of the three DOE facilities in Oak Ridge,
TN. There also were some individuals in the database that were interested parties but
they did not have BeS or CBD (e.g., health care providers). The precise number of
people in the database without BeS or CBD is unknown but was estimated at 50 people
for response rate calculations. To maintain patient confidentiality, packets of information
were provided to the SOMD who distributed them to the people in the database via the
U.S. Postal Service or e-mail. Those wishing to participate responded directly to the
researcher. The identities of those not choosing to participate remained confidential to
the SOMD. There was significant overlap between people attending the BSGOR and
the SOMD database. Recipients were instructed in the cover letter to ignore the mailing
if they had already elected to participate at a BSGOR meeting. An estimated 209
potential participants were contacted via the SOMD direct mailing.
Third, a similar confidential mailing was made by National Jewish Health to
patients who were current or former workers from the DOE Complex with either BeS or
CBD. Patient confidentiality was maintained in the same manner as with the Y-12
SOMD. There was some overlap between this database and the other two methods.
The precise amount of overlap is unknown, but was estimated at 75 people for
response rate calculations. Recipients were instructed in the cover letter to ignore the
mailing if they already had elected to participate. Thirteen packets were returned as not
deliverable or because the person was deceased. The number of potential participants
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reached by this method was 299. A total of 588 potential participants were contacted
via the three methods described.
Four questionnaires were used to collect data for the study. Questionnaires are
not reprinted in this manuscript due to copyright restrictions. All instruments were
reviewed by beryllium subject matter experts, the University of Tennessee and U.S.
Department of Energy Institutional Review Boards (IRB) and key advisors from the
BSGOR. Instruments were field tested prior to administration of the survey. A
demographic and work history questionnaire was developed for this study. This
instrument collected standard demographic information (e.g., age, gender, race, etc.) as
well as information about work history (e.g., location, job titles, duration, etc.,) and
disease status (e.g., BeS diagnosis, CBD diagnosis, dates, etc.). Results were entered
into an Excel® spreadsheet.
The SF-36v2® Health Survey (QualityMetric, Inc.) was used to measure the
health-related quality of life of the participants. The validity and reliability of this
instrument have been previously demonstrated. [for example: Findler 2001] This
instrument collected information on eight domains: physical functioning, role-physical,
bodily pain, general health, vitality, social functioning, role-emotional, and mental health.
The data were used to calculate a Physical Component Summary (PCS) and Mental
Component Summary (MCS) for each participant. The data were converted to t-scores
and compared to a sample from the general U.S. population (Quality Metric 2009
General Population Sample). Each scale had the same mean (50) and standard
deviation (10). A scale score below 50 indicated a health status below average relative
to the general U.S. population [Ware 2001]. The scoring algorithms and t-scores were
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calculated by QualityMetric Health Outcomes™ Scoring Software 4.5, provided by
QualityMetric, Inc.
The Mishel Uncertainty in Illness Scale – Community Form (MUIS-C) was used
to measure uncertainty in illness. The reliabilities for the MUIS-C are reported as
moderate to high (α = 0.74 to 0.92) [Mishel 1997]. The MUIS-C has six primary
domains: 1) ambiguity, 2) inconsistency, 3) vagueness, 4) unpredictability, 5) lack of
information, and 6) unfamiliarity. The 23-item Likert-format scale provided a single total
score with a possible range from 23 to 115 with a midrange score of 69. The MUIS-C
produces scores in the direction of higher uncertainty. Data from completed MUIS-C
questionnaires were entered into and scored in Excel®.
The Psychosocial Adjustment to Illness Scale – Self Report (PAIS-SR®) was
used to assess the participants’ psychosocial adjustment to their medical condition. The
validity and reliability of the instrument have been previously reported [for example:
Derogatis 1986]. There are seven principal domains of the PAIS®, all of which have
been shown to have a high relevancy for adjustment to medical illness. The domains
include: 1) health care orientation, 2) vocational empowerment, 3) domestic
environment, 4) sexual relationships, 5) extended family relationships, 6) social
environment, and 7) psychological distress. Data from completed questionnaires were
entered and scored by software provided by the vendor (Clinical Psychometric
Research Inc.). Raw scores were used for analysis. Higher scores indicate poorer
adjustment [Derogatis 1990].
Several measures were taken to help assure data quality. Returned
questionnaires were reviewed for completeness. When possible, follow-up inquiries
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were made with participants to collect missing or incomplete data. The principal
researcher verified the accuracy of data entry by comparing each completed
questionnaire directly to data entered into the spreadsheet, making corrections as
necessary. Scattergrams were produced to identify outlier scores. When extremely high
and low scores were identified, the researcher returned to the raw data file to determine
if there were missing data that influenced the score. If that was the case, that score was
coded as missing. Statistical analysis was performed using IBM® SPSS® Statistics 19.
This study was approved by the University of Tennessee and DOE IRBs. Written
informed consent was obtained from study participants.

Results
The sample population consisted of 126 volunteers with either BeS or CBD who
were either currently working at or were retired from DOE Facilities. Twenty-five (20%)
of the participants were enrolled as a result of presentations to the BSGOR. Nine (7%)
of the participants were enrolled via direct mail from the Y-12 SOMD. The remaining 92
participants (73%) were enrolled via direct mail from National Jewish Health. Four
packets were returned but were not useable due to incompleteness or they were
received after the deadline. The combined response rate was 22% (130/588).
The participants were predominately married, white and male, with some college
or trade school education. Half of the group was retired. The demographics of the
sample population are provided in Table 3.2. Most of the participants work or worked at
one of five DOE facilities: Y-12 (Oak Ridge, TN), Rocky Flats (Golden, CO), Hanford
(Richland, WA), Kansas City Plant (Kansas City, MO) or Pantex (Amarillo, TX). This
distribution of cases by DOE site is similar to that reported in the Former Worker
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Medical Screening Program Annual Report [Department of Energy 2011b] and the
Beryllium Associated Worker Registry Summary [Department of Energy 2011a]. The
distribution of participants with CBD and BeS by DOE site is presented in Table 3.3.
Table43.2. Demographic characteristics of study participants
Variable
Participants
Age

Gender
Marital status

Race

Education

Household income

Work status

Description
Total
Range (years)
Median
Mean
Male
Female
Married
Divorced
Other
White
White Hispanic
African American
Other
<High school diploma
High school or GED
Some college/ trade school
Associates degree
Bachelor degree
Graduate degree
$0-25,000
$25-50,000
$50-75,000
$75-100,000
>$100,000
Not disclosed
Working
Retired
Medical leave
Looking for work

Frequency
126
42-85
62.5
63.6
93
33
106
12
5
105
12
7
2
1
21
59
20
10
15
8
32
31
22
18
15
52
63
9
2

Percent
100
73.8
26.2
86.2
9.8
4.0
83.3
9.5
5.6
1.6
0.8
16.7
46.8
15.9
7.9
11.9
6.3
25.4
24.6
17.5
14.3
11.9
41.3
50.0
7.1
1.6
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5 Table 3.3. Distribution of participants by disease status and Department of Energy site
Current
Former
Total
DOE Site
Workers
Workers
CBD
BeS
N
CBD
BeS
Y-12
7
15
7
5
34
Rocky Flats
3
3
8
8
22
Hanford
1
6
7
6
20
Kansas City Plant
3
5
2
10
20
Pantex
2
7
1
1
11
Los Alamos Nat Lab
2
0
4
2
8
Nevada Test Site
0
2
2
0
4
Idaho Nat Lab
0
0
1
2
3
Lawrence Livermore Nat Lab
0
0
1
1
2
Oak Ridge Nat Lab
0
0
1
0
1
Sandia Nat Labs
0
1
0
0
1
Total
18
39
34
35
126
DOE=Department of Energy; BeS=beryllium sensitization; CBD=chronic beryllium
disease; Nat=National; Lab=Laboratory

%
27.0
17.5
15.9
15.9
8.7
6.3
3.1
2.4
1.6
0.8
0.8
100

All of the participants reported that they had been told by a physician that they
had BeS or CBD. Fifty two (52, 41.3%) of the participants had been diagnosed with
CBD while the remainder (74, 58.7%) were BeS. Participants who were BeS had been
sensitized an average of 9.9 years with a range of 1 to 24 years. Those with CBD had
the diagnosis an average of 8.8 years with a range of <1 to 24 years.
The results of the SF-36v2® Health Survey indicated that the participants had
worse health than the normative population (Quality Metric 2009 General Population
Sample). This was true for the Physical Component Summary (PCS), Mental
Component Summary (MCS), and all domains (general health, physical functioning, role
physical, bodily pain, vitality, social functioning, and role emotional).
SF-36v2® Health Survey results for participants with CBD were compared to
results for participants with BeS. The two-independent-sample t-test was used to test
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the null hypothesis that the mean scores of the two groups were equal. The results
indicated that the mean PCS score for participants with CBD was not equal to the mean
score for participants with BeS (p=.038). The null hypothesis was rejected for the PCS.
All other mean scores were not significantly different. Table 3.4 provides the results of
the SF-36v2® Health Survey.

6Table 3.4. Results of the SF-36v2® Health Survey
Survey Component and Domains

Mean Score

CBD
BeS
Physical Component Summary
39.1*
43.2
Physical Functioning
40.8
43.2
Role Physical
40.9
43.7
Bodily Pain
42.4
45.0
General Health
39.1
41.8
Mental Component Summary
47.1
46.4
Vitality
44.6
44.5
Social Functioning
43.6
44.1
Role Emotional
42.5
44.1
Mental Health
48.2
47.3
* p=.038, t-test (2-tailed); BeS=beryllium sensitization; CBD=chronic beryllium disease
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The MUIS-C Survey results for participants with CBD were compared to the
results for those with BeS. The two-independent-sample t-test was used to test the null
hypothesis that the mean scores of the two groups were equal. The results indicated
that the mean MUIS-C score for participants with CBD was not significantly different
from the mean score for participants with BeS. The null hypothesis was not rejected.
Table 3.5 provides the results of the MUIS-C Survey.

7Table 3.5. Results of the Mishel Uncertainty in Illness Scale–Community Form (MUISC) Survey
Disease Status

N

Mean Score

CBD
50
68.3
BeS
71
68.1
Total
121
68.2
Missing=5; BeS=beryllium sensitization; CBD=chronic beryllium disease

Standard
Deviation
12.9
10.8
11.6

The PAIS-SR® survey results for participants with CBD were compared to results
for participants with BeS. The two-independent-sample t-test was used to test the null
hypothesis that the mean scores of the two groups were equal. The results indicated
that the mean overall PAIS-SR® score for participants with CBD was significantly
greater (p=.02) than the mean overall score for participants with BeS. The null
hypothesis was rejected for the overall PAIS-SR® score. The mean scores for four of
seven PAIS-SR® domains were also significantly different: healthcare orientation
(p=.003), vocational environment (p=.003), domestic environment (p=.02), sexual
relationships (p=.02), and social environment (p=.04). Table 3.6 provides the results of
the PAIS-SR® Survey.
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8 Table 3.6. Results of the Psychosocial Adjustment to Illness Scale–Self Report (PAISSR®) Survey

Domain

Mean Score

CBD
BeS
Overall Score
433.7*
411.7
Healthcare Orientation
62.9
63.9
Vocational Environment
63.6**
59.5
Domestic Environment
63.4*
57.8
Sexual Relationships
63.7*
59.1
Extended Family Relationships
62.5
59.6
Social Environment
61.4***
58.3
Psychological Distress
56.3
53.4
* p=.02, t-test (2-tailed), ** p=.003, t-test (2-tailed), ***p=.04, t-test (2-tailed)
BeS=beryllium sensitization; CBD=chronic beryllium disease

Correlational analysis was conducted to evaluate the relationships between the
scores for PAIS-SR®, MUIS-C, and SF-36v2® Health Survey. Pearson’s Product
Moment Correlation Coefficients (2-tailed) were calculated to determine the direction of
correlation and strength of association. The data were grouped into CBD and BeS
subsets for analyses. Several statistically significant relationships were identified.
The PCS and MCS scores showed a moderate, positive correlation for
participants with BeS (r=.33, p=0.01) indicating that mental health scores increased as
physical health scores increased.
The PAIS-SR® scores had a moderate, negative correlation with MCS for those
with CBD (r=-.31, p<0.05) and BeS (r=-.45, p<0.001). The PAIS-SR® scores had a
weak, negative correlation with PCS for those with CBD (r=-.24) and a moderate,
negative correlation for those with BeS (r=-.42, p<0.001).
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The PAIS-SR® scores had a strong positive relationship with the MUIS-C scores
for those with CBD (r=.62, p<.001) and BeS (r=.59, p<.001). The MUIS-C scores had a
weak, negative correlation with PCS and MCS scores for all participants. Table 3.7
summarizes the correlational analyses.

9Table 3.7. Correlation matrix for SF-36v2® Health Survey, Psychosocial Adjustment to
Illness Scale–Self Report (PAIS-SR®) Survey and Mishel Uncertainty in Illness Scale–
Community Form (MUIS-C) Survey scores
Disease Status
MCS
PCS
PAIS-SR®
MUIS-C
CBD
MCS
1
PCS
.26
1
PAIS-SR®
-.31*
-.24
1
MUIS-C
-.21
-.21
.62***
1
BeS
MCS
1
PCS
.33**
1
PAIS-SR®
-.45**
-.42**
1
MUIS-C
-.23
-.23
.59***
1
*significant at the 0.05 level (Pearson Correlation, 2-tailed)
**significant at the 0.01 level (Pearson Correlation, 2-tailed)
***significant at the 0.001 level (Pearson Correlation, 2-tailed)
BeS=beryllium sensitization; CBD=chronic beryllium disease; MCS=mental component
summary; PCS=physical component summary
Regression analysis was performed to determine the best predictors of the
psychosocial effects of BeS and CBD. MCS was selected as the dependent variable
and the domains of the PAIS-SR® were selected as the independent variables. Five
outlier MCS values were trimmed from the dataset for the analysis. The null hypothesis
was that there was no linear relationship between the variables.
A multiple regression model including psychological distress, social environment
and domestic environment as the independent variables best predicted the MCS score.
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for the domain of psychological distress. The domain of psychological distress
measures dysphoric thoughts and feelings that accompany the individual’s disorder as
indicated by anxiety, depression, hostility, reduced self-esteem, body image problems,
and inappropriate guilt [Derogatis 1990]. The domain of social environment reflects the
status of the participant’s current social and leisure time activities and the degree to
which the participant has suffered impairment or constriction of these activities as a
result of their illness [Derogatis 1990]. The domain of domestic environment is oriented
toward illness-induced difficulties that arise primarily in the home or family environment.
It is designed to assess problems in adaptation experienced by the participant and their
family unit in response to the participant’s illness [Derogatis 1990].
Those variables accounted for 30% of the variability in the model (R2=0.304).
Healthcare orientation, vocational environment, sexual relationships and extended
family relationships were not statistically significant and were excluded from the model.
The null hypothesis was rejected (ANOVA, F=16.3, p<0.001).
Gender and BeS status were selected as control variables and the data was reanalyzed. Females had a higher R2 than males (0.40 vs. 0.19) and those with BeS had
a higher R2 than those with CBD (0.33 vs. 0.22). Additional analyses were conducted
controlling for age, income, and retirement status. None of those variables had a
significant effect on the model. Table 3.8 and Figure 3.1 summarize the multiple
regression model.
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10Table 3.8.Multiple regression model to predict mental component summary scores
Unstandardized
Coefficients
B
Standard Error

Variable
(Constant)
Psychological
distress
Social
environment
Domestic
environment

Standardized
Coefficients
Beta

t

Significance

81.7

6.59

-

12.4

<0.001

-0.48

0.12

-0.44

3.78

<0.001

-0.56

0.17

-0.41

3.30

0.001

0.40

0.14

0.36

2.84

0.005

Independent
Variables

Dependent
Variable

Social
Environment

Psychological
Distress

Mental
Component
Summary
Score

Domestic
Environment

5 Figure

3.1.Multiple regression model path analysis
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Discussion and Conclusions
The results of this study support the model of the psychosocial effects of CBD
[Miller 2012]. In the model, uncertainty was proposed as an independent variable that
influenced health quality of life, the dependent variable. Psychosocial adjustment was
proposed as an intermediate variable that mediated the effects of uncertainty. This
model suggested that as uncertainty increased, health quality of life decreased unless
the effects were mediated by the ability to make psychosocial adjustments to the illness.
Figure 3.1 illustrates the model and the correlations between the variables that were
measured in this study.
Controlling Variables
(Potential Confounders)
•
•
•
•
•
•

Antecedents
•
•
•
•
•

Genetic susceptibility
Exposure
Sensitization
Symptoms of disease
CBD diagnosis
Independent Variable
Uncertainty
MUIS-C
•
•
•
•
•
•

Dependent Variable
Health Quality of Life
SF-36v2®

(-) correlation

Ambiguity
Inconsistency
Vagueness
Unpredictability
Lack of information
Unfamiliarity

(+) correlation

Age
Education
Socioeconomic status
Vocation
Marital Status
Healthcare experiences

Intermediate Variable
Psychosocial Adjustment
PAIS-SR®
•
•

Healthcare orientation
Vocational environment

•
•

Sexual relationships
Extended family relationships

• Domestic environment

•
•
•
•
•
•
•
•

Vitality
Physical functioning
Bodily pain
General health perceptions
Physical role functioning
Emotional role functioning
Social role functioning
Mental health

(-) correlation

• Social environment
• Psychological distress

Figure63.2. Relationships between variables in the model of the psychosocial effects of
beryllium sensitization and chronic beryllium disease
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The direction and strength of the correlations between uncertainty and health
quality of life (negative correlation, moderate strength) supported the theoretical model.
That is, as uncertainty increased the health quality of life decreased. This suggests that
efforts to reduce uncertainty (e.g., providing information and education) may help
mitigate the negative effect that uncertainty has on health quality of life. It appears this
is important for those with BeS as well as those with CBD so interventions to reduce
uncertainty are important for both segments of the population.
The strong positive relationship between the PAIS-SR® scores and the MUIS-C
scores indicated that greater uncertainty (i.e., high MUIS-C scores) was associated with
a poorer ability to adjust to illness (i.e., high PAIS-SR® score). The analysis provides
evidence that as uncertainty in illness increases the inability to make psychosocial
adjustments to illness also increases. This suggests that the uncertainty of BeS or CBD
may overwhelm the coping strategies of individuals and indicate the need for
interventions that reduce uncertainty and improve psychosocial adjustment skills.
Finally, the negative correlation between the PAIS-SR® scores and MCS/PCS
scores suggest that those who were less effective at making psychosocial adjustments
(i.e., mediating uncertainty) had poorer health quality of life (i.e., lower scores).
Because of this relationship, it can be hypothesized that those with BeS or CBD could
benefit from interventions that help them develop new or varied coping strategies to
mediate uncertainty and adjust to their illness.
There are many reasons why a person may have a high MCS score. The
multiple regression model indicated that psychological distress, social environment and
domestic environment had a linear relationship with MCS score and may therefore be
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important targets for intervention programs. Interventions through medical providers
and/or support groups may best serve their patients/participants by focusing on
psychological distress, social environment and domestic environment coping strategies
for those with BeS and CBD.
These variables accounted for only 30% of the variability in the model so there is
important research to be done to explain the remaining variability in the model. With a
larger dataset, one could further explore models that differentiate psychosocial effects
between men and women and between those with BeS and CBD.
Comparison of the mean scores for all of the mental health scales indicated the
same trend; those with BeS had scores similar to those with CBD. This suggests that
BeS may have as much, and possibly more, impact on one’s mental health than CBD.
An alternate explanation is that those with CBD have already progressed through the
more psychologically damaging phase of BeS and are more resolved to their status with
CBD.
This research describes the psychosocial effects of BeS and CBD and fills a gap
in our understanding of the spectrum of the disease. These results have implications
for treatment as well as workers compensation. Currently, compensation is linked to the
physical signs and symptoms of CBD while BeS is not compensable under most
workers compensation insurance programs. These results suggest that insurance
coverage/compensation for counseling and treatment for psychological distress and
other mental health components may be warranted for those with BeS.
Several findings support the notion that the mental health aspects are an
important feature of BeS. The MCS and PCS mean scores from the SF-36v2® Health

150

Survey suggest that BeS manifests itself primarily in the mental health domain while the
physical aspects are secondary. When CBD develops, the physical aspects increase
while the mental health aspects appear to remain an important factor. It was not
surprising that the mean PCS score were significantly lower for those with CBD. Many
of these participants reported moderate to severe physical disability associated with
their disease. This was in contrast to participants with BeS who often reported no
physical symptoms.
The mean MCS score was equal for participants with CBD and BeS. Those with
BeS actually had higher mean scores on the MCS and three of four mental health
domains when compared to those with CBD. While not statistically significant, these
data suggest that BeS may have as much impact on mental health as CBD. Supporting
this notion was the PAIS-SR® score for the domain of psychological distress (i.e.,
having dysphoric thoughts and feelings that accompany the individual’s disorder). The
scores were not significantly different for those with CBD compared to those with BeS.
This may indicate that those with BeS have dysphoric thoughts and feelings similar to
those who have CBD.
The mean PAIS-SR® score for the domain of healthcare orientation was actually
higher for those with BeS when compared to those with CBD. This result suggests that
those participants with BeS have a more negative healthcare posture (i.e., attitude,
quality of information, and expectations for treatment) and that may impede their ability
to adjust to their medical condition.
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The mean MUIS-C scores were approximately equal for those with CBD and
those with BeS. This is consistent with the results for the MCS and the PAIS-SR®
psychological distress domain.
There are limitations to this study that must be considered when interpreting the
results. The sample population may not be representative of the larger study population.
The lack of a central BeS/CBD database, patient confidentiality requirements, the
geographic dispersion of cases across the U.S., and limited resources made access to
the entire study population difficult. The response rate from those who were contacted
was also low. These factors contributed to a small sample size. Information was selfreported by the participants. No attempt was made to medically verify self-reported
information. The cross-sectional nature of the study design also has inherent limitations
that impact the ability to draw conclusions about cause and effect based on the study
results. Due to these limitations, inferences based on these results about the larger
DOE population or for beryllium workers in private industry may not be valid.
Future research that demonstrates the reliability of the SF-36v2® Health Survey,
PAIS-SR®, and MUIS-C questionnaires for people with BeS or CBD would provide
assurance that they were appropriate for this study. Further analysis to describe the
specific types of uncertainty in the study population would be a key next step in
designing intervention programs.
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